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ABBREVIATIONS
3ch = three-chamber
AF = atrial fibrillation
ATP = adenosine triphosphate
BMI = body mass index
BSA = body surface area
CAD = coronary artery disease
CMR = cardiovascular magnetic resonance
Cr = creatine
CVD = cardiovascular disease
EDV = end diastolic volume
EF = ejection fraction
ESV = end systolic volume
FFA = free fatty acid
1H-MRS = proton magnetic resonance spectroscopy
HF = heart failure
HDL = high-density lipoprotein cholesterol
HOMA-IR = homeostasis model assessment of insulin resistance
Hs-CRP = high-sensitivity C-reactive protein
LA = left atrium
LDL = low-density lipoprotein cholesterol
LV = left ventricle
LVGFI = left ventricular global function index
MetS = metabolic syndrome
MRI = magnetic resonance imaging
NT-proBNP = N-terminal pro-brain natriuretic peptide
NASH = non-alcoholic steatohepatitis
NAFLD = non-alcoholic fatty liver disease
31P-MRS = phosphorus magnetic resonance spectroscopy
PCr = phosphocreatine
PFR = peak filling rate
SA = short axis
SAT = subcutaneous adipose tissue
SV = stroke volume
T2DM = type 2 diabetes mellitus
TG = triglyceride
VAT = visceral adipose tissue
VLDL = very low-density lipoprotein cholesterol
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ABSTRACT
verweight and obesity are major global health concerns affecting around 2
billion people worldwide. Abdominal obesity is particularly hazardous to
health associating with metabolic syndrome (MetS), non-alcoholic fatty
liver disease (NAFLD), and type 2 diabetes mellitus (T2DM). In MetS, ectopic
fat accumulates around the viscera and into organs regularly containing only minor
amount of adipose tissue. This cross-sectional study was conceived to discover
effects of MetS and ectopic adiposity including myocardial steatosis on cardiac
function in non-diabetic men free of known heart diseases. The gold standard non-
invasive method for fat quantification, proton magnetic resonance spectroscopy,
was used to measure hepatic and myocardial triglyceride (TG) content. Magnetic
resonance imaging (MRI) was used to assess cardiac structure and function and to
quantify epicardial, pericardial, subcutaneous, and visceral abdominal fat depots.
First, we examined the components of cardiac adiposity and their relationship
to intra-abdominal ectopic fat deposits and cardiometabolic risk factors. MetS was
associated with an increase in all examined ectopic fat depots. Myocardial TG was
twofold increased in MetS. However, visceral adipose tissue (VAT) was the best
independent predictor of cardiometabolic risk factors.
Secondly, we studied left ventricular (LV) diastolic function and its relationship
with cardiac fat depots. MetS associated with LV diastolic dysfunction and
concentric LV remodeling. However, myocardial TG content was not an independent
predictor of LV diastolic dysfunction.
Thirdly, we studied the effect of different ectopic fat depots on LV structure and
function in subjects with NAFLD and searched the role of hepatic fat content on
cardiac steatosis. Epicardial and pericardial adipose tissue as well as myocardial TG
content accumulated with increasing amount of both hepatic TG content and VAT.
In addition, hepatic steatosis and VAT were associated with LV diastolic
dysfunction.
Lastly, we studied left atrial (LA) structure and function in MetS and examined
the association of different ectopic fat depots and cardiometabolic risk factors with
possible LA dysfunction. MetS associated with subclinical LA dysfunction without
enlargement of the LA. Moreover, LA dysfunction associated with several
contributory factors of MetS including waist circumference, insulin resistance,
dyslipidemia, and VAT, which was the best independent predictor of LA dysfunction.
Notably, the role of myocardial TG content on LA function remained inconclusive.
In conclusion, MetS associates with significant changes in the structure and
function of the heart. These changes are subclinical but may be followed by late
complications such as heart failure or atrial fibrillation. The value of cardiovascular
MRI may be early recognition of those obese subjects at risk for developing
cardiovascular disease. Instead of body mass index, VAT is the best predictor of
cardiac dysfunction. This study highlights the fundamental role of visceral obesity
and hepatic steatosis directing their harmful effects to risk of cardiovascular
diseases. The role of myocardial TG on cardiac dysfunction remains indeterminate.
Therefore, cardiac energetics and the dynamic role of intramyocytic lipids, which
are the primary fuel of the heart, merit further study.
O
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TIIVISTELMÄ
lipaino ja lihavuus ovat maailmanlaajuisia terveysongelmia koskettaen noin
kahta miljardia ihmistä. Keskivartalolihavuus on erityisen haitallista tervey-
delle liitännäissairauksiensa kuten metabolisen oireyhtymän (MBO), alko-
holiin liittymättömän rasvamaksataudin ja tyypin 2 diabeteksen vuoksi. MBO:ään
liittyy rasvan kertyminen sisäelinten ympärille (viskeraalirasva) sekä varsinaisen
rasvakudoksen ulkopuolelle (ektooppinen rasva) kuten sisäelimiin.
Väitöskirjatyössä selvitettiin MBO:n vaikutuksia sydämen toimintaan ja sydä-
men rasvoittumisen roolia kardiometabolisena riskitekijänä miehillä, joilla ei ollut
diabetesta tai tiedossa olevia sydäntauteja. Sydänlihaksen ja maksasolujen sisäistä
rasva- eli triglyseridipitoisuutta mitattiin kajoamattomasti protonimagneettispekt-
roskopian avulla. Sydämen rakennetta ja toimintaa, sydäntä ympäröivää epi- ja
perikardiaalirasvaa sekä vatsan alueen ihonalais- ja viskeraalirasvaa tutkittiin
magneettikuvauksella.
Tutkimme maksan rasvoittumisen, ihonalais- ja viskeraalirasvan sekä sydämen
eri rasvaosioiden suhdetta toisiinsa. Osoitimme, että MBO:ssä ektooppisen rasvan
määrä oli kasvanut ja sydänlihaksen rasvapitoisuus oli kaksinkertainen. Viskeraali-
rasvan määrä oli paras itsenäinen kardiometabolisten riskitekijöiden ennustaja.
Tutkimme sydämen vasemman kammion toimintaa ja sen yhteyttä sydämen
rasvatiloihin. Sydämen vasemman kammion diastolinen toiminta oli alentunut
MBO:ssä ja siihen liittyi konsentrista kammion uudelleenmuotoutumista.
Vasemman kammion diastolisella vajaatoiminnalla ei ollut yhteyttä sydänlihaksen
triglyseridipitoisuuteen.
Tutkimme sydämen ja muiden ektooppisten rasvakertymien roolia sydämen
diastolisen vajaatoiminnan kehittymisessä ja maksan rasvoittumisen yhteyttä
sydänlihaksen triglyseridipitoisuuteen. Epi- ja perikardiaalirasvan määrä sekä
sydänlihaksen triglyseridipitoisuus korreloivat maksan ja viskeraalialueen rasvaan.
Maksan rasvoittumisaste ja viskeraalirasvan määrä korreloivat lisäksi sydämen
vasemman kammion diastoliseen vajaatoimintaan.
Selvitimme sydämen vasemman eteisen rakennetta ja toimintaa henkilöillä,
joilla oli MBO, ja ektooppisten rasvakertymien sekä kardiovaskulaaristen
riskitekijöiden vaikutusta niihin. Sydämen vasemman eteisen toiminta oli
heikentynyt ilman eteisen koon muutosta. Vasemman eteisen vajaatoiminta oli
yhteydessä useaan MBO:n osatekijään, kuten vyötärönympärys, insuliiniresistenssi,
rasva-aineenvaihdunnan häiriöt ja viskeraalirasvan määrä, joista viimeksi mainittu
oli paras itsenäinen ennustetekijä. Eteisen vajaatoiminta ei korreloinut
sydänlihaksen rasvan määrään.
Löysimme sydämen magneettikuvauksella MBO-potilailta merkittäviä
sydämen rakenteen ja toiminnan piileviä muutoksia, joiden mahdollisia myöhäis-
komplikaatiota ovat sydämen vajaatoiminta ja eteisvärinä. Viskeraalirasvan määrä
oli paras ennustetekijä piileville sydämen toiminnan häiriöille. Viskeraalirasvalla ja
rasvamaksalla on tärkeä rooli lihavuuden haitallisten sydänvaikutusten systee-
misenä välittäjänä. Osoitimme, että sydämen triglyseridipitoisuus lisääntyy
MBO:ssä ja alkoholiin liittymättömässä rasvamaksataudissa, mutta sen rooli
sydämen toiminnan häiriöiden kehittymisessä jäi avoimeksi. Sydämen
energiatalous ja sydämen pääenergialähteenä toimivien lipidien dynaaminen rooli
ovat otollisia kohteita jatkotutkimuksille.
Y
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INTRODUCTION
rigins of obesity can be traced back to prehistoric times when those of our
ancestors who stored energy in the most effective way would best survive
fast and famine [1].  While sedentary lifestyle and overabundance of
calories now prevail in most parts of the world, the long-term result of
natural selection has turned against us. Consequently, overweight and obesity have
exploded to major global health concerns [2].
Obesity does not come alone but is often accompanied by a variety of comorbid
conditions such as hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM),
non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MetS). It was
not until the 20th century when the connection between obesity and cardiovascular
diseases (CVD) was solidified [3].  Now, we know that one of the main risk factors
of coronary artery disease (CAD), heart failure (HF), and atrial fibrillation (AF) is
obesity [4]. We don’t, however, fully understand the pathophysiological
mechanisms linking these diseases. Increasing evidence shows that the location of
fat matters. Centrally obese people are particularly prone to develop MetS and
cardiovascular complications of obesity and to have a deadly outcome [5]. In MetS,
excess fat is stored not only around the visceral organs but also in non-adipose
tissue such as liver, pancreas, skeletal muscle, and heart.
Liver is a key organ in lipid and carbohydrate metabolism and thus an essential
player in obesity and MetS. The main organ to bear the deleterious consequences
of these diseases is the heart. Modern non-invasive imaging techniques have
revolutionized the quantification of ectopic fat accumulation in living humans [5].
With magnetic resonance spectroscopy (MRS), fat accumulation or lipid content of
both liver and heart can be reliably quantified [6]. With magnetic resonance
imaging (MRI), subcutaneous and the deep-lying visceral fat can be separated and
the pericardial and epicardial fat embracing the heart can be measured accurately
[6]. Additionally, MRI provides a three-dimensional assessment of the structure
and function of the heart.
In the studies presented here, we have utilized MRS and MRI to study the role
of MetS, ectopic fat depots, and clinical cardiometabolic risk factors in cardiac
function in Finnish men free of known heart diseases. The themes of focus are
distribution of ectopic fat, cardiac steatosis, left ventricular (LV) diastolic function,
left atrial (LA) function, and influence of NAFLD.
O
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REVIEW OF THE LITERATURE
1 Obesity
1.1 Prevalence and terminology
verweight and obesity are major global health concerns of epidemic scale
[2]. Obesity is generally estimated by the ratio of weight over height and
the most commonly used anthropometric index is the body mass index
(BMI) expressed in kilograms per meter squared. Among adults, a healthy
weight corresponds to a BMI between 18.5 and 24.9 kg/m2. BMI between 25.0 and
29.9 kg/m2 is overweight, and BMI of ≥30.0 kg/m2 is obese. The degree of obesity
is further classified according to the BMI value where BMI of 30.0 to 34.9 kg/m2 is
class 1 or mild obesity, 35.0 to 39.9 kg/m2 is class 2 or moderate obesity, and ≥40.0
kg/m2 is class 3 or severe or morbid obesity [7].
In 2016, more than 1.9 billion adults (39% of men and 40% of women) were
overweight and of these, 650 million (11% of men and 15% of women) were obese
[2]. Between 1975 and 2016, the worldwide prevalence of obesity has nearly
tripled. Today, most of the world's population live in countries where overweight
and obesity kill more people than underweight [2].
In Finland, according to FINRISK 2012 health study, over 50% of adults were
at least overweight and over 20% were obese [8]. The prevalence of overweight or
higher was 65% in men and 46% in women. Regardless of gender, obesity was
equally common.
1.2 Measurements of obesity
Even though BMI is a commonly used and suitable anthropometric index of obesity
at the population level, it has been criticized because of its inability to differentiate
between fat mass and lean body mass [9]. Thus, adults with normal weight but
excess body fat may not be diagnosed as overweight or obese. Conversely,
individuals with high levels of lean body mass may be misclassified as overweight
or obese. Additionally, it is a relatively poor index of regional body fat distribution.
In 1980s it was reported that a simple index of regional body fat distribution,
the ratio of waist-to-hip circumferences, was more strongly correlated to metabolic
complications and to cardiovascular outcomes than the BMI [10, 11].  Afterwards,
multiple studies confirmed that the regional distribution of body fat was more
important than excess adiposity in initiating the CVD risk associated with a certain
excess of body weight or fat [5].
During the last decades, waist circumference has been promoted as an ideal
inexpensive clinical complementary measurement to BMI for assessing obesity. It
is a simple yet effective way to assess for central obesity, with excellent correlation
with abdominal imaging and high association with CVD risk and mortality [12, 13].
O
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Consequently, definitions of the MetS have adapted waist circumference as a
surrogate marker of abdominal or central obesity.
Waist circumference and BMI are not, however, very useful to comprehend the
mechanisms by which body fat composition affect health risks. Waist
circumference is primarily an index of total adiposity that is influenced by
abdominal adiposity. An essential finding derived from studies involving cross-
sectional imaging such as CT and MRI is that waist circumference, however, cannot
distinguish visceral from subcutaneous abdominal adipose tissue [5]. Waist
circumference may thus be increased due to abdominal subcutaneous or visceral
adipose tissue (VAT) depots, or both.
The use of modern imaging enables precise and reliable quantification of
differences in body fat distribution. The ability to store fat in various adipose tissue
compartments can considerably differ from one individual to another. Generally,
most of the body energy is stored in subcutaneous adipose tissue (SAT). Some
individuals, however, can accumulate large amounts of adipose tissue in their
abdominal cavity. An excess of intra-abdominal fat or VAT has been reported to be
deleterious and associated with a set of metabolic abnormalities including insulin
resistance, hyperinsulinemia, glucose intolerance, T2DM, atherogenic dyslipidemia
(high serum TG, high LDL, and low HDL), inflammation, adverse cytokine profile,
impaired fibrinolysis, increased risk of thrombosis, and endothelial dysfunction [5,
14]. Excess of VAT can be thus considered as a good marker of an altered
cardiometabolic risk profile predictive of increased risk of T2DM and CVD.
1.2.1 Assessment of body fat composition
Various techniques have been used to assess body tissue composition and fat
distribution. These techniques include, skinfold thickness measurements,
underwater weighting, near-infrared interactance, air displacement
plethysmography, and biometric impedance analysis.
Among imaging methods, dual-energy X-ray absorptiometry and ultrasound
have been used in clinical setting to assess regional body fat distribution. CT and
MRI have, however, revolutionized the study of fat distribution and body
composition, and are therefore considered to be the gold standard for calibration
of other methods estimating adipose tissue and lean body mass [7]. In both CT and
MRI, the measurement of subcutaneous and visceral fat is typically performed at
the level of lumbar spine.
1.3 Obesity complications
A wide spectrum of co-morbidities is associated with overweight and obesity [15].
T2DM, MetS, and CVDs, including hypertension, dyslipidemias, CAD, and HF are
discussed in detail later in the thesis. Vascular risk factors all increase the risk for
neurological complications such as stroke, dementia, and Alzheimer’s disease.
Obstructive sleep apnea and asthma are common complications of obesity
regarding respiratory system. Gastrointestinal complications of obesity include
non-alcoholic fatty liver disease (NAFLD), which is discussed later in the thesis,
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unfavorable changes of the gut microbiome, and increased risk of pancreatitis,
gallstones, and gastroesophageal reflux disease. Obesity is a major cause of colon,
breast, endometrial, renal, and esophageal cancer. It is also associated with
increased risk of gastric, pancreatic and gallbladder cancer, as well as leukemia. An
obese person is in chronic low-level inflammatory state which has been proposed
to be a central mechanism connecting obesity to its metabolic and vascular
complications. Other common complications or risks of obesity include impaired
renal function, urinary tract stones, gout, infertility, osteoarthritis, and depression.
As a result of a wide spectrum of increased morbidity, obesity associates with
a decreased life expectancy [16].
2 Metabolic syndrome
2.1 Introduction
The importance of abdominal fat and association with hypertension and
atherosclerosis was recognized as early as 1765 by the Italian anatomist Giovanni
Baptista Morgagni [1, 17]. In the 1920s, the coincident relationships between
metabolic abnormalities such as hyperglycemia, hypertension, and hyperuricemia
were further documented [17]. These findings were important groundwork for the
disease now known as metabolic syndrome, a clustering of coincident risk factors
including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia,
low high-density lipoprotein (HDL) cholesterol, and hypertension [17]. The
syndrome originally known as syndrome X was first conceptualized by Reaven in
1988 [18].
Two primary factors for the development of MetS are adult weight gain with
body fat accumulation, and a tendency to store fat in intra-abdominal sites,
including ectopic fat in liver, pancreas and heart [19]. MetS is strongly associated
with a lifestyle characterized by physical inactivity and unlimited supply of food
with high calorie and low nutrition content [19]. However, due to the high
individual variation and genetic and epigenetic factors for both the components
and expression of the syndrome, not all individuals at risk develop MetS [19].
The original idea of MetS focused on the crucial role of insulin resistance which
is clearly an important and associated feature of MetS [18]. Before the
establishment of harmonized criteria for MetS in 2009, it was debated whether
MetS should be considered a true syndrome or a mixture of risk factors [20-22].
The concept of MetS was claimed to have an unclear definition, limited value in
clinical practice, and there were doubts regarding its value as a CVD risk marker
[20, 23]. One of the defending arguments for MetS was that the diagnosis of MetS
provides a focus on the cluster of CVD and diabetes risk factors that require
attention and it emphasizes the multifactorial nature of the risk for these diseases
[22]. Other benefits of the diagnosis of MetS include the emphasis it places on
central obesity and the ability of MetS to identify high-risk individuals at a young
age [24]. It also provides a useful metric for the scale and progress of global obesity,
diabetes and CVD epidemic [24].
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Today, it is well accepted that the combination of components of MetS
represent a pathologic state that substantially augments risk for the development
of T2DM and CVD [17]. Thus, recently the focus has been on MetS as an
epidemiologic tool related to CVD risk [17]. Because each component of MetS is an
independent risk factor for CVD, together they produce a large variety of vascular
and cardiac diseases [17].
2.2 Prevalence
MetS is a growing epidemic in parallel with the obesity epidemic. It has been
estimated that ~30% of overweight and ~60% of obese men and women meet the
criteria for the diagnosis of MetS [17]. In adults, the prevalence of MetS in most
European countries is 10-30% and in the United States up to 40% [19].
2.3 Clinical criteria for MetS
Diagnostic criteria of MetS have been variably defined by a number of organizations
[19]. The most commonly used criteria in Europe is adopted by International
Diabetes Federation (IDF). IDF Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; and International Association
for the Study of Obesity published a guideline to harmonize the definition of the
MetS in 2009 [25]. This definition recognizes that the risk associated with waist
circumference will vary in different populations. For the Europid people the
suggested cutoff for waist circumference is ≥94 cm for men and ≥80 cm for women.
Higher thresholds (≥102 cm for men and ≥88 cm for women) are used as the waist
circumference cut points to identify MetS in the United States. Lower waist cutoff
points varying in different countries are recommended for Asian population.
Notably, the American values are consistent with the American definition of
abdominal obesity which equate to a BMI of approximately 30 kg/m2 (also WHO
criteria for obesity) in males. The European values are, however, closer to a BMI of
25 kg/m2 in males (WHO criteria for overweight).
In addition to waist circumference, four other diagnostic criteria for the
diagnosis of MetS are: elevated TGs (≥1.7 mmol/l), reduced HDL cholesterol (<1.0
mmol/l in males, <1.3 mmol/l in females), elevated blood pressure (systolic ≥130
mmHg and/or diastolic ≥85 mmHg), and elevated fasting glucose (≥5.6 mmol/l).
Drug treatment for these conditions are alternate indicators. The original IDF
criteria for MetS was defined by large waist circumference plus two other findings.
According to the 2009 harmonized criteria, waist can be considered as one of the
five criteria and 3 abnormal findings out of 5 will qualify a person for MetS [25].
2.4 Insulin resistance
In muscle and liver, one main role of insulin is the regulation of glucose uptake. In
adipose tissue, insulin promotes adipogenesis by increasing fatty acid uptake and
esterification and the synthesis of TG and inhibiting lipolysis [26]. In insulin
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resistant individuals, there is greater demand for insulin secretion by the
pancreatic β cells to facilitate peripheral glucose uptake leading to
hyperinsulinemia. In adipose tissue, the dose-response to insulin-lipolysis is
declined, leading to adipose tissue insulin resistance. Adipose tissue insulin
resistance has been found to increase proportionally to visceral and hepatic fat and
associate with the severity of NAFLD [26].
Excess free fatty acid (FFA) overflow is the central cause of insulin resistance
and metabolic dysfunction [26]. FFAs derive from adipose tissue, hepatic de novo
lipogenesis, or overflow from plasma TG. Obese adipose tissue expansion occurs
through the enlargement of adipocyte size (hypertrophy) or the increase in
adipocyte number (hyperplasia) [26]. As adipocyte hypertrophy is correlated with
insulin resistance, it has been hypothesized that adipose tissue becomes
dysfunctional when it cannot expand in response to excess caloric intake,
eventually leading to the storage of excess lipids into visceral fat and ectopic fat
[26]. On the other hand, if the function and insulin-sensitivity of the SAT is
preserved and it is able to expand through hyperplasia, the subject will be protected
against the development of MetS despite the positive energy balance [5].
Most people with MetS have both abdominal obesity and insulin resistance
[25]. Insulin resistance is closely related to impaired glucose tolerance, T2DM and
risk of CAD, augmenting morbidity and mortality risk [19]. Compared to general
population, the risk for T2DM in MetS is 5-fold [25]. All MetS patients do not,
however, develop insulin resistance due to high individual variety and complex
contributing factors. Specifically, about a third of patients with MetS have normal
insulin sensitivity [19].
3 Ectopic fat accumulation
3.1 Introduction
Excess caloric consumption and sedentary lifestyle combined with unfavorable
genotype and several environmental factors result in lipid overflow due to failure
of SAT to expand and store the excess of circulating FFAs. As a result, ectopic fat
accumulates around the viscera and into sites mainly containing only minor
amount of adipose tissue, such as the liver, pancreas, skeletal muscle, and heart [5,
7]. The resulting metabolic consequences are the features defining MetS as
previously described.
Ectopic fat deposits have been classified into those with local and those with
systemic effects [27]. According to this, perivascular, myocardial, epi/pericardial,
and renal sinus fat have mainly local unfavorable effects, whereas VAT, or fat in the
liver or skeletal muscles have systemic effects due to the important role of these
organs in glucose, insulin, and lipid metabolism. For this reason, both the amount
and location of ectopic adipose tissue are highly important with respect to the
cardiovascular morbidity and mortality. Pathophysiology of VAT accumulation is
reviewed in the following paragraph, whereas cardiac fat depots and hepatic fat are
revised later in the thesis.
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3.2 Visceral adipose tissue
In addition to the role of insulin resistance discussed in the previous chapter,
several theories have been proposed to explain the deposition and harmfulness of
VAT. From the embryological aspect, intra-abdominal fat has its origin as brown
adipose tissue exhibiting greater mitochondrial density and rates of lipolysis and
glycolysis than the subcutaneous white adipose tissue [19]. Intraabdominal fat
appears thus primarily to be involved in high-turnover distribution of FFAs to other
body organs. When intraabdominal fat enlarges into a fat storage, however,
metabolic complications arise.
One theory to explain the link between visceral obesity and cardiometabolic
risk burden is called the portal FFA hypothesis. According to this, expanded visceral
fat depot exposes, through its lipolytic activity, the liver to high concentrations of
FFAs [28]. This leads to impaired liver metabolism and contributes to the
hyperglycemic, hyper-insulinemic, and hyper-triglyceridemic state. Controverting
the portal FFA theory, it has, however, been shown that 80% of FFAs found in the
portal circulation are from systemic adipose tissue [29].
Another theory explaining visceral obesity is the overactivation of
hypothalamic-pituitary-adrenal axis leading to an increased control of
carbohydrate and lipid metabolism by glucocorticoids [30].  It has been shown that
visceral adipocytes have more glucocorticoid receptors than subcutaneous adipose
cells. Therefore, overactivation of hypothalamic-pituitary-adrenal axis may induce
fat deposition in the VAT while concurrently inducing insulin resistance in the liver
and in the skeletal muscle.
Gonadal steroids play a major role in the regulation of adipose tissue
distribution, function, and storage [31]. In men, low testosterone levels are
associated with higher adiposity and visceral fat deposition [32]. In women,
estrogens are considered responsible for the gluteal–femoral fat distribution [33].
After menopause, a transition toward an android visceral fat distribution occurs,
presumably due to decreasing estrogen levels [31]. The same phenomenon has also
been reported in studies regarding transsexual patients receiving appropriate
steroid hormone replacement therapy [5].  Estrogen and gluteal-femoral fat
favoring adipose tissue distribution seems to protect women from type 2 diabetes
[33]. On the other hand, although visceral fat deposition is more common in men, it
seems to have more detrimental effects in women. In a recent population-based
study, abdominal SAT and VAT were associated with insulin resistance to a similar
extent in men, whereas in women particularly VAT was associated with insulin
resistance and insulin secretion [34].
Overactivation of the endocannabinoid system is another disturbance in
hormonal milieu associated with excess visceral obesity [5]. In obese individuals,
endocannabinoids, released from adipose tissue and involved in feeding behavior,
energy metabolism as well as glucose and lipid metabolism are increased via
insulin resistance and inflammation. Increased plasma endocannabinoid levels
may stimulate the overexpression of cannabinoid receptors in a pathophysiological
manner contributing to excessive visceral fat accumulation and decreases in
adiponectin level [9, 35].
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It is estimated that genetic factors contribute about 30% of the observed
variance in BMI but about 70% of the variance in fat distribution that relates more
to the MetS [36]. However, also epigenetic mechanisms such as poor intra-uterine
growth and maternal smoking (during pregnancy or early infancy) exist which can
determine the preference to store excess body fat in intra-abdominal and ectopic
sites already in very early life [19]. Recognized lifestyle factors that increase the
intra-abdominal fat are weight gain, a diet high in saturated fat, smoking, inactivity,
and excess alcohol intake [19]. Overweight subjects with a high level of
cardiorespiratory fitness have been characterized by low levels of VAT in
comparison with BMI-matched overweight individuals with low cardiorespiratory
fitness [37]. Although smokers tend to have lower BMI values than nonsmokers,
they have more abdominal adipose tissue and more insulin resistance than
nonsmokers [38]. Another important correlate of individual varieties in VAT is
ethnicity. Whites have a greater susceptibility of VAT deposition than blacks [39].
Asian populations are more prone to VAT deposition at lower BMI values, and
therefore at risk to develop T2DM at lower BMI values than whites [5, 40].
4 Cardiac function in obesity and metabolic syndrome
4.1 Cardiovascular risk
Obesity has been linked to development of CVDs including atherosclerosis, CAD, HF,
and AF [4]. Obesity increases the risk of CVD secondarily through its impact on the
development and severity of comorbidities such as hypertension, dyslipidemia, and
insulin resistance or diabetes. It is estimated that a single unit increment in BMI
leads to 4% increased risk of ischemic stroke, 6% increased risk of hemorrhagic
stroke, 6% increased risk of HF, and 4% increased risk of AF [4]. A 10 kg increment
in body weight results in 12% increased risk of CAD, 3 mmHg higher systolic blood
pressure, and 2.3 mmHg higher diastolic blood pressure [4].
Obesity is an independent risk factor for the development of CAD. A strong,
inverse linear relationship between BMI and earlier age of first myocardial infarct
has been reported [41, 42]. In a meta-analysis of 190 672 subjects, adults who were
obese had an earlier onset of incident CVD, a greater proportion of life lived with
CVD morbidity, and shorter overall survival compared with adults with normal BMI
[43]. The authors concluded that “the obesity paradox” (meaning a greater
longevity after diagnosis of CVD for obese and overweight individuals), appears
largely to be caused by earlier diagnosis of CVD.
In a meta-analysis of 87 studies and 951 083 patients, MetS more than doubled
the risk of CVD, myocardial infarction, and stroke [44]. MetS was associated with a
2-fold increase in risk of CVD mortality, and a 1.5-fold increase in risk of all-cause
mortality. In the absence of T2DM, MetS was still associated with a 1.8-fold increase
in risk of CVD mortality and stroke, and 1.6-fold risk in myocardial infarction.
The association between MetS and HF is strong [45]. It is estimated that obesity
doubles the risk of developing HF after adjustment for associated co-morbidities
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[46]. Furthermore, the prevalence of insulin resistance is up to 60% in patients
affected by HF [45].
4.1.1 The ‘healthy obesity’ paradox
Although being overweight and obese are strong risk factors for CVD, significant
individual differences are observed in the cardiometabolic risk profile of subjects
within the same BMI category [9]. In some obese patients, favorable metabolic
features such as high levels of insulin sensitivity and HDL-cholesterol as well as low
levels of fasting triglycerides (TG) and fasting glucose were observed, and a unique
obesity phenotype known as ‘metabolically healthy obesity’ was introduced [47].
Furthermore, some studies reported that metabolically healthy obesity was not
associated with an increased risk of CV mortality compared with normal weight
individuals [48]. The definition of metabolically healthy in these studies has,
however, been variable, and moreover, they have had a relatively short follow-up
period of 10 years or less [9].
In two recent meta-analyses, it was shown that metabolically healthy obese
phenotype should no longer be considered as a benign condition. One analysis,
including 61 386 people with a follow-up period of more than 10 years, reported
that metabolically healthy obesity was associated with an increased risk for all-
cause mortality and CVD events [49]. Another meta-analysis involving 299 059
individuals, demonstrated a 100% increased risk for CVD events in the
metabolically healthy obese group [50].
Although younger individuals may appear to have metabolically healthy
obesity, they may with increasing age develop insulin resistance, diabetes,
dyslipidemia, and arterial hypertension, defining MetS [9]. Thus, one must not
disregard the long-term CV hazards of being characterized by an apparently benign
obesity phenotype and the necessity to follow these patients over the long-term.
4.2 Hemodynamic changes
Traditionally, excess adipose tissue has been associated with increased blood
volume and cardiac output [3, 51]. According to this concept, the presence of excess
adipose as well as non-adipose tissue results in increased blood volume. The
increase in blood volume prompts venous return to the right heart and increases
LV preload. Through the Frank–Starling mechanism, the increase in preload
increases stroke volume. As the change in heart rate with obesity is small or absent,
this ultimately leads to increased cardiac output. Simultaneously, the increased
preload leads to increased ventricular wall tension which in chronic condition may
lead to chamber dilatation and contribute to HF. Additionally, afterload is increased
due to coexisting hypertension, further escalating myocardial demand,
contributing to cardiac remodeling, left ventricular hypertrophy (LVH), and the
development of HF.
Recently, this concept has been questioned and the relationship between
obesity and LV structure and function seems to be more complex than presumed
[52]. It has been reported that blood flow per unit of adipose tissue is relatively low
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at 2 to 3 ml/min and is insufficient to fully account for the high cardiac output state.
High cardiac output may not even be present in all forms of obesity. One
explanation may relate to the role of body fat distribution. Recent findings suggest
that in central obesity, cardiac output is lower and systemic vascular resistance is
higher than in peripherally located obesity [53].
4.3 Morphological changes of the heart
In autopsy studies before the age of non-invasive cardiac imaging, elevated heart
weight and left ventricular hypertrophy were main findings associated with obesity
[3]. Echocardiography and CMR have revolutionized the non-invasive assessment
of cardiac morphology in overweight and obesity, but data concerning the
incidence of cardiac chamber enlargement and LVH has been inconsistent. Based
primarily on echocardiographic evaluation, the following incidence values have
been reported: increased LV mass (6%–87%), increased LV wall thickness (6%–
56%), increased LV diastolic dimension (8%–40%), LA dilatation (10%–50%) and
right ventricle enlargement (32%) [3]. The large variation of results attributes to
variation in severity of obesity, duration of obesity, and presence or absence of
associated morbidities. Echocardiographic data regarding cardiac remodeling in
obesity has mainly pointed towards eccentric cardiac remodeling where both LV
mass and EDV are increased [3]. However, several opposite findings reporting
concentric remodeling have also been published recently [52, 54]. Notably, the
commonly used method for measuring chamber wall thickness in one dimension
for the assessment of LVH and remodeling index with echocardiography is more
prone to errors than measuring LV mass with CMR.
In a population-based CMR study of 997 subjects, LV mass and EDV correlated
with BMI as well, but out of these two, only LV mass correlated with VAT [55].  In
another large population-based CMR study of 5098 participants aged 45 to 84 and
excluded for clinical heart diseases, LV mass and EDV were positively associated
with BMI for both sexes [56]. Increasing levels of obesity were associated with
concentric LV remodeling, expressed by increased LV mass-to-volume ratio which
was due to a greater increase in LV mass relative to LV EDV. In men, as opposed to
women, association of concentric remodeling and overweight or obesity remained
significant after adjustment for cardiovascular risk factors including hypertension.
CMR studies examining the role of MetS or relationship of VAT and other fat
depots with LV morphology are limited [55, 57, 58], or have not comprehensively
examined the impact of body fat distribution on LV concentric remodeling. In a
study of 110 subjects, concentric LV remodeling was associated with abdominal
obesity, and only 20% of the subjects presenting with concentric remodeling had
LVH [58].
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4.4 Left ventricular function
4.4.1 Systolic function
LV systolic function is typically preserved in obesity [3].  Most studies comparing
LV ejection fraction in obese and lean subjects have reported no significant
differences between these groups. Even in morbid obesity, severe LV systolic
dysfunction is rare in the absence of co-existing heart disease. In severe obesity,
exercise induced rise in LV systolic function is, however, restrained in the presence
of LV hypertrophy [59].
4.4.2 Diastolic function
Normal diastolic function allows the LV to fill at rest and during exercise without
abnormal increase in diastolic pressure [60]. Diastolic function is influenced by LV
volume and geometry, contractile coordination, heart rate, LV relaxation and
stiffness, and the pericardium. Diastolic ventricular function consists of four
phases: isovolumic relaxation, early rapid filling, diastasis and atrial filling [3]. In a
healthy heart, the majority of LV filling takes place during the early diastolic phase
and is the result of a suction effect caused by myocardial relaxation. Atrial
contraction is responsible of the late filling phase where a minority of the filling
occurs. Myocardial relaxation is an active and energy-consuming process that is
related to uptake of calcium from contracted myocytes via sarco/endoplasmic
reticulum Ca2+-ATPase [60]. Stiffness (elastance) which is a passive process,
depends on LV morphology (geometry, mass), viscoelastic properties of the LV
(fibrosis), and the properties of the pericardium. Diastolic dysfunction is associated
with considerable abnormalities of these two closely linked processes; LV active
relaxation and stiffness [60].
LV diastolic function can be assessed with various invasive or noninvasive
imaging modalities [60]. Left-sided heart catheterization and the measurement of
LV diastolic pressure is the standard of reference for assessment of LV diastolic
function. This procedure cannot, however, be justified routinely due to its
invasiveness. Trans-thoracic echocardiography is the most commonly used method
in clinical practice because of its availability and excellent temporal resolution.
Echocardiographic assessment of diastolic function is typically based on the
measurement of trans-mitral flow velocity which has various pitfalls [60] and is
reported to be inaccurate in cases of normal LV EF [61]. CMR is considered the gold
standard for the assessment of LV volumes and systolic function due to superior
image quality, especially over echocardiography, high reproducibility, excellent
spatial and sufficient temporal resolution, and with minimal operator variability,
and without limitations of acoustic window or choice of imaging volume [60, 62].
Analysis of LV volume versus time curve has proved to be a reliable method to
assess diastolic dysfunction with CMR [63, 64].
LV filling pressure is frequently elevated in classes 2 and 3 obese individuals,
and increases substantially with exercise, often exceeding the threshold likely to
produce pulmonary edema [3]. In echocardiographic studies, LV diastolic filling has
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been shown to be impaired in obese and MetS subjects relative to lean subjects [3,
65, 66]. Additionally, increasing body weight (BMI or severity of obesity) correlates
with greater impairment of LV diastolic filling [3, 67]. Correlation of LV mass to
impaired diastolic function has been variable [3]. CMR studies concerning diastolic
dysfunction in obesity or MetS allowing precise LV filling pattern analysis are
limited [14,15].
4.4.3 Obesity cardiomyopathy
Obesity cardiomyopathy may be defined as HF that is due entirely or
predominantly to obesity [3].  Obesity cardiomyopathy occurs mainly in class 3 or
super-obese patients who have usually been severely obese for more than 10 years.
Common co-morbidities of obesity cardiomyopathy include obstructive sleep
apnea, AF, and typical symptoms include fatigue, shortness of breath, and lower
extremity edema [52]. Endomyocardial biopsies revealed cardiac myocyte
hypertrophy in obese subjects referred for HF investigations [68]. In addition,
patients with obesity were less likely (23.3% vs 64.5% in lean subjects) to have a
specific etiology diagnosed for their HF, suggesting an obesity specific
cardiomyopathy.
However, thorough assessment of comparative contribution of obesity to the
development of HF is difficult. Obesity is a major risk factor for hypertension, which
contributes to the development of CAD, and associates with abnormal LV geometry
and subsequent HF. Obesity is also linked to other cardiovascular risk factors such
as diabetes mellitus, dyslipidemia, and inflammation, and relates to a low level of
cardiorespiratory fitness which itself is a potent risk factor for HF [52]. CMR studies
on specific findings in obesity cardiomyopathy have not been reported.
4.5 Left atrial function and atrial fibrillation
LA function is important for maintaining optimal cardiac performance in three
distinct phases. 1) During LV systole LA acts as a reservoir of pulmonary venous
return. 2) At the early LV diastole, it serves as a conduit and its function is adjusted
by LV diastolic performance. 3) At the late phase of LV diastole, LA acts as a pump
improving LV filling. In HF, with sustained increases in LV and LA pressure, LA
dilatation ensues, and LA contractile reserve becomes diminished. In end-stage HF,
this leads to a change of LA to a passive conduit dictated by ventricular
distensibility [69]. In AF, the pump function of LA is lost due to dyssynchronous
contraction of cardiomyocytes.
AF is the most common cardiac rhythm disorder and is associated with
significant morbidity and mortality, especially that arising from stroke and HF [70,
71]. Obesity represents the second highest population-based risk for AF after
hypertension and it has been estimated that almost 1 in 5 cases of AF can be
attributable to overweight or obesity [72]. Multiple studies have identified LA size
as an independent predictor of AF [73]. In obese patients without AF, LA
enlargement has been related to hypertension and LV dysfunction [3]. However,
CMR data regarding LA function in MetS is very limited.
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Atrial remodeling is defined as a spectrum of pathophysiological changes in
atrial structure and function that occur in response to stresses imposed by
conditions such as hypertension, HF, T2DM, and obesity [74]. Atrial remodeling
may be subdivided to structural remodeling, as measured by LA size, and
mechanical remodeling, as measured by LA function. Decreased LA EF, which is a
functional index of LA, seems to be a better measurement to correlate with LV end-
diastolic pressure than maximum LA volume [75]. Chronically increased LV filling
pressure, obtained during invasive heart catheterization, results in LA remodeling
over time [76]. Milder, often subclinical forms of atrial dysfunction may thus show
decreased LA EF without LA enlargement.
The pathophysiological mechanisms of atrial remodeling and development of
AF in obesity are, however, complex and remain elusive. In addition to major risk
factors (male sex, HF, CAD, diabetes, sleep apnea, smoking, and excessive alcohol
use), they include unfavorable genotype, impaired diastolic function causing atrial
stretch, focal adiposity, and inflammation resulting in scar tissue [71]. As a result,
structural, functional and electrical changes occur comprising the substrate for AF.
5 Cardiac adiposity
5.1 Introduction
Excess fat deposition involving the heart of obese persons was first described by
Senac in 1783 [3]. In 1806, Corvisart described adipose tissue surrounding the
heart and suggested that in obese people the heart was “oppressed by enveloping
fat that sometimes caused sudden death”. Laennec first established the fatty heart
entity in 1819, distinguishing between “fatty surcharge on the surface of the heart”
and “fatty degeneration in which muscular substance was transformed into fat
exhibiting pallor like dead leaves”. In 1933, Smith and Willius published a study of
post-mortem cardiac findings of 135 obese adults.  They found that heart weight
was increased in proportion to the degree of obesity and was far greater than
expected in extremely obese persons. Moreover, almost all subjects had excess
epicardial fat, whereas myocardial fat content was normal in most individuals. In
later half of the 20th century, the idea of coronary obstruction as the central
pathogenetic mechanism of CVD supplanted the role of cardiac adiposity [77]. A
renewed interest in cardiac adiposity has risen in the new millennium, particularly
as the result of the rapid development in the field of noninvasive imaging, making
it possible to quantify ectopic fat masses and contents with increasing levels of
accuracy. Current findings indicate that adiposity, inflammation, and arterial
obstruction are simultaneously operative in modulating tissue ischemia and plaque
vulnerability [77].
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5.2 Terminology
Heart-related fat can be divided into myocardial, epicardial, and pericardial fat (Fig.
1) [77, 78]. Myocardial fat content refers to TG droplets stored within the
cardiomyocytes. Epicardial fat is the layer of adipose tissue between the
myocardium and the visceral sheet of pericardium. Pericardial fat refers to the
continuum of the thoracic or mediastinal adipose tissue sitting outside the parietal
pericardium. In the literature, the term pericardial fat has different meanings. It has
been used to describe epicardial and/or pericardial individually and it has been
used to refer to both adipose deposits together. Sometimes, it has also been called
paracardial fat [79]. To avoid confusion, the terms described above are used in the
thesis similarly as in the original articles.
5.3 Myocardial fat
In proportion to its mass, heart is the most energy consuming organ in the human
body [80]. Approximately 6 kg of ATP is utilized in the myocardium every day.
Depending on the availability and demand, normal heart can generate its energy
from lipids, glucose, amino acids, ketone bodies and lactate [80]. However, the
dominant energy source of the myocardium is fatty acid oxidation. Circulating
levels of FFA determine the cardiac fatty acid uptake which occurs through passive
diffusion and active fatty acid transport proteins. In the resting state, a majority
(70-90%) of fatty acids entering cardiomyocytes are rapidly used for ATP
synthesis, whereas a minority (10-30%) of fatty acids are stored in the intracellular
myocardial lipid pool [80].
Obesity and MetS are associated with ectopic deposition of lipids in non-
adipose tissue including the heart. A formation of organs’ steatosis is defined as the
presence of an abnormally high levels of TG droplets in the cytosol of non-adipose
cells (such as cardiomyocytes in the heart) [81]. Non-adipose cells are not,
however, designed to retain large amount of TG for an extended time.
Figure 1. A T1-weighted short-axis-
oriented MR image demonstrates
heart-related fat stores; fat in the
myocardium (white arrow),
epicardial fat (gray arrow), and
pericardial fat (black arrow).
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Consequently, the disproportionately high amount of TGs are eventually shunted
into non-oxidative pathways resulting in the accumulation of toxic lipid species
leading to condition called lipotoxicity [82]. Lipotoxicity has detrimental metabolic
consequences including impairment of glucose metabolism, lipid oxidation and cell
signaling, leading to oxidative stress, mitochondrial defects, apoptosis, and organ
dysfunction [82]. Animal studies have provided evidence on a close relationship
between cardiac lipotoxicity and impaired LV function [82].
In recent years, 1H-MRS has allowed noninvasive quantification of
cardiomyocytic TG content in living humans [83]. Based on 1H-MRS evaluation,
normal heart in lean individual contains less than 1.0% TG of the organ mass.
Increased cardiac adiposity has been associated with obesity, impaired glucose
tolerance, and T2DM where up to four-fold increases of myocardial TG content may
occur [84-86]. In T2DM patients, myocardial TG content has been associated with
LV diastolic dysfunction [87, 88] and concentric LV remodeling [85]. However, the
mechanism behind this phenomenon has remained unresolved, and controversial
reports have been published [86].
5.4 Epicardial and pericardial fat
5.4.1 Anatomy and embryology
Epicardial fat is a metabolically active fat deposit located within the pericardium
and in direct contact with the myocardium and coronary vessels which provide its
vascular supply [77]. Epicardial fat originates from a population of mesothelial cells
that migrate onto the surface of the heart from the area of the septum transversum
which is the embryological source of the diaphragm [89]. Epicardial fat, along with
mesenteric and omental fat, develop from the splanchnopleuric mesoderm
associated with the gut. In the normal adult, epicardial fat is concentrated in the
atrioventricular and interventricular grooves and along the major coronary artery
branches, and, secondarily, around the atria, over the free wall of the right ventricle
and over the apex of the LV.
Pericardial fat lies on the external surface of the parietal pericardium within
the mediastinum. It does not have a distinct outer border, because it is a continuum
of the mediastinal adipose tissue. Pericardial fat originates from the primitive
thoracic mesenchyme which divides to form the parietal (fibrous) pericardium and
the outer thoracic wall [89]. Vascular supply of the pericardial fat differs from that
of the epicardial fat. Pericardial fat receives its supply from multiple sources
including the pericardiacophrenic artery, a branch of the internal mammary artery.
5.4.2 Function and clinical significance
Animal studies have demonstrated that epicardial fat shows higher lipogenic and
lipolytic activities than other fat deposits [90]. Still, the physiology of lipid storage
in human epicardial fat is poorly understood [91]. Epicardial fat has been suspected
to serve as a local site of energy storage in the form of FFAs and as a protective
buffer against high levels of FFAs and TG accumulation in the myocardium [79].
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However, no direct evidence exist verifying the buffering action or demonstrating
for reverse FFA movement from epicardial fat into the myocardium [91].
Furthermore, uneven distribution of epicardial fat over the surface of the heart
would be unfavorable, if it was a source of FFA for the pumping heart.
Epicardial fat, located mainly around the coronary arteries in lean subjects,
may serve a supportive, mechanical purpose, reducing vascular tension and torsion
[77]. However, excess epicardial fat may cause adverse mechanical effects by
tapering the myocardial relaxation and increasing myocardial stiffness.
In the Framingham Heart Study, epicardial fat was associated with obesity and
higher LV mass [55]. Iozzo et al. have reported that epicardial fat associates with
LV remodeling (although not independently) and visceral fat [85]. In
echocardiographic studies, epicardial fat has been associated with MetS and LV
diastolic dysfunction [78, 92]. Numerous studies have linked epicardial adipose
tissue to increased AF burden [93].
In obese patients, epicardial adipose tissue secretes proinflammatory
cytokines with a role in coronary atherogenesis [89]. Increasing evidence indicate
that epicardial fat contributes also to clinical CAD. In a recent meta-analysis of 70
studies comprising 41 534 subjects, associations between CT-based assessment of
epicardial adipose tissue volume and CAD were studied [94]. Epicardial fat was
independently associated with coronary artery stenosis, myocardial ischemia, and
major adverse cardiovascular events but not with coronary artery calcification.
Pericardial fat has been proposed to play roles in thermogenesis and
supporting and mechanical purposes, such as attenuating vascular tension and
torsion [95].
5.5 Assessing cardiac adiposity
5.5.1 Magnetic resonance spectroscopy of the myocardium
5.5.1.1 Introduction
The first pioneering acquisition of 1H-MRS cardiac data was performed in 1984 in
an intact, perfused rat heart by Ugurbil et al. [96]. The first human cardiac spectrum
in vivo was recorded a decade later [97]. More disciplined studies utilizing localized
cardiac spectroscopy in vivo became possible another decade later, after
introduction of the two key technological elements: 1) sequences for spatial
localization and 2) methods for the compensation and synchronization of the
acquisition with respiratory motion and heart beating [98].
Currently, MRS allows the non-invasive biochemical analysis of in vivo changes
in cardiac metabolism by detecting metabolites with proton (1H) and phosphorus
(31P) nuclei in the human heart [99]. Cardiac 1H-MRS is mostly used for the
detection of myocardial TG. Other myocardial metabolites such as taurine,
carnitine, and total creatine can also be detected and quantified by 1H-MRS, but
experimental procedures for these metabolites are technically more challenging
because of low concentrations and overlapping frequencies [98].
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Cardiac 31P-MRS can be used to assess cardiac energy status by detecting the
metabolites such as adenosine triphosphate (ATP) and phosphocreatine (PCr) [99].
However, relative MR sensitivity of phosphorus is about 15 times lower than that
of a proton. For 1H-MRS, usually the same radiofrequency (RF) coils can be used as
for MRI, whereas 31P-MRS requires dedicated 31P coils and a second (multi-nuclei)
RF channel [99].
5.5.1.2 MRS technique
As in conventional MRI, an RF pulse is applied, and the signal from the tissue is
measured and Fourier transformed in MRS [100]. In MRI, frequency variation is
used for spatial localization of the signal to a voxel to create a cross-sectional image.
However, in MRS, the resonance frequency is used to separate and characterize the
metabolites or chemicals within the voxel [100]. Further chemical information
about tissue is captured from the signal intensity and the line width which may be
used to detect the relative quantity of the chemical. The frequency shift or location
of chemicals relative to that of water enables to generate qualitative and
quantitative information about the chemicals that occur within tissues, forming the
basis of MRS [100].
Nuclei suitable for nuclear magnetic resonance have an odd number of either
protons or neutrons, which provides them with a quantum mechanical magnetic
moment [101]. In a magnetic field, such nuclei align and precess at distinct
quantized orientations and resonant frequencies. When excited with an RF field,
flips between orientations occur and at the resonant frequency result in RF
emissions and absorptions which can be detected with a tuned RF coil [101]. In a
proton spectrum at 1.5 T, the metabolites are distributed between 63-64 MHz
[100]. Resonance frequencies are commonly expressed as parts per million (ppm)
to allow comparison of spectral measurements at different field strengths and to
avoid the use of large numbers. In the ppm scale, the resonance of a chemical
describes its position along the x-axis, where tetramethylsilane is commonly used
as a zero reference (Fig. 2). Because the configuration of proton and electron
interaction within chemical chains determines the resonance of a compound, it is
possible to use the chemical shift to identify chemical compounds. The signal
intensity, or height, of the metabolite peak, visualized as the amplitude measured
along the y-axis, and the line width provide the area under a particular metabolite
peak which can be used to quantify the amount of observed chemical compound
within the voxel of interest [100]. There is no absolute scale (or unit) for the y-axis
and the resulting metabolite concentrations are therefore usually reported as
metabolite ratios to a presumably stable metabolite occurring naturally in tissue,
such as water [100]. Following spectral acquisition, spectral analysis needs to be
performed with dedicated software.
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Due to constant contractile and respiratory motion and blood flow, the heart is
a particularly challenging target to image and to collect spectra. However, ECG-
triggered and respiratory gated 1H-MRS has proved to be a valid and reproducible
method for non-invasive measurement of cardiomyocytic TG content in humans
[83]. Cardiac 1H-MRS is typically performed by single-voxel techniques such as
stimulated echo acquisition mode (STEAM) or point-resolved spectroscopy
(PRESS). The spectrum shows the resonances for water, TG (fat, lipids), and total
creatine [102]. The spectrum is dominated by the signal from water which can
interfere with the detection and quantification of signals from the metabolite
moiety of interest. Such interference may occur when the dynamic range of the MR
receiver is limited, when the concentration of moieties are <0.1% of water, and/or
when they are complicated by broad spectral side-wings or intense motion artifacts
spreading from the water signal peak [101]. The lipid (TG) spectrum consists of
multiple peaks, where the dominant peaks are caused by the resonance of methyl
(-CH3) protons and methylene (-CH2) in the TG molecule [100]. The size of the lipid
peak relative to that of the water peak increases with the amount of TG content. To
counter the dominance of the water peak and to weigh the relative metabolite
content to the tissue water signal, spectra with and without water-suppression are
acquired from the same voxel in the myocardium [99].
To prevent contamination from the epicardial fat, a voxel of interest is
generally positioned in the interventricular septum [99]. The size of the voxel is
usually large enough to average out local inhomogeneities in the myocardial fat
distribution and to provide enough signal-to-noise ratio to permit a suitably short
acquisition time for data collection [98]. If the voxel size is larger than the septal
wall thickness, the spectrum may also include water signal from blood resulting in
an underestimation of metabolite concentrations [99].  Another limitation of the
technique is that septal TG content may not represent the global TG content









Figure 2. 1H chemical shift ranges for some common organic moieties.
TMS=tetramethylsilane. (Modified from Bottomley 2015, reproduced with
permission of John Wiley and Sons.)
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5.5.1.3 Other applications of 1H-MRS
Protons have the highest natural abundance among nuclei suitable for
spectroscopy. Therefore, MRS applications in humans have tended to focus mostly
on the 1H nucleus [103]. The most widely studied organ is the brain where
metabolites of numerous diseases including brain tumors, epilepsy, multiple
sclerosis, and stroke have been investigated. In addition to the brain, prostate and
breast have been other main organs for cancer studies [103]. The use of MRS in
routine clinical practice, however, remains to be established. Regarding energy
metabolism and diabetes, skeletal muscle has earlier been the main research target
until the recent interest in cardiac MRS. Another important target for 1H-MRS
studies is the liver.
5.5.2 Imaging of epicardial fat
Most commonly used imaging techniques to measure epicardial fat are
echocardiography, CT, and MRI [79].  Echocardiography is the cheapest and usually
most easily available option for the evaluation of epicardial fat. It is limited by
acoustic shadows especially in obese patients. Studies using echocardiography
usually measure epicardial fat thickness on the free wall of right
ventricle.  Although echocardiography is highly operator-dependent, good intra-
and interobserver reproducibility and moderately strong correlation with the
thickness measurement and volume assessment of epicardial fat have been
reported [79, 104]. However, epicardial fat is not evenly distributed over the heart
and it is questionable whether thickness measurement on a single location can truly
reflect the total epicardial fat burden.
Both CT and MRI provide accurate volumetric measurement of epicardial
adipose tissue and have high intra- and interobserver reproducibility [79].
Epicardial fat assessment using CT and MRI has been shown to generate
comparable results [105]. Advantages of CT imaging are that coronary artery
calcium score may be calculated, and CT angiography may be performed to rule out
and assess CAD non-invasively. As for cardiac MRI, a wide spectrum of applications
is available from functional analyses to evaluation of different pathologies,
including myocardial ischemia, myocarditis, and cardiomyopathies. Even though
semi-automated techniques may be used for epicardial fat quantification, data
analysis for both CT and MRI can be time consuming. Other disadvantages of MRI
include high cost, limited availability and lengthy image acquisition. Radiation
exposure is a major drawback of CT, as compared to echocardiography and MRI
[79].
MRI provides an accurate tool to quantify epicardial fat. In T1- and T2-
weighted images, epicardial fat shows as a high intensity fat layer between the
intermediate signal myocardium and the low-intensity visceral pericardium. ECG-
triggering or cine sequences are required to standardize the measurement for the
phase of the cardiac cycle. Quantifying the whole epicardial adipose tissue volume
is time consuming even with semi-automated techniques. Therefore, area-based
measurements are commonly used [106]. Novel techniques such as 3D Dixon
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sequence with fat-only images may prove useful for accurate computer-aided
quantification of epicardial fat [107].
5.5.3 Imaging of pericardial fat
As mentioned before, due to various definitions and the lack of distinct surrounding
fascia, quantification methods of pericardial fat are variable in the literature. For
the analysis of pericardial fat, echocardiography provides very limited value.
Contrary to the epicardial fat, where the fat exists in typical locations such as
atrioventricular and interventricular grooves, pericardial fat is unevenly
distributed over the parietal pericardium.
Both CT and MRI may be used for quantification of pericardial fat. The
measured volume or area must be standardized, i.e. limited to a certain volume or
a single slice [106, 108]. The same MRI techniques as described above for epicardial
fat are valid also for assessment of pericardial fat.
6 Non-alcoholic fatty liver disease
6.1 Introduction
Patients with MetS often have excessive fat accumulation in the form of TGs in the
liver and hepatic insulin resistance [109]. In the absence of other known causes of
steatosis (e.g., alcohol, viruses, drugs), this condition is called non-alcoholic fatty
liver disease (NAFLD). NAFLD is a spectrum of chronic liver diseases ranging from
simple fatty liver to non-alcoholic steatohepatitis (NASH) which can progress to
fibrosis, cirrhosis, and liver failure. Furthermore, NAFLD is an emerging risk factor
of hepatocellular carcinoma which can develop even without cirrhosis in patients
with NAFLD [109, 110]. Although NAFLD has been reported to be a common cause
of incidentally discovered elevated liver enzymes, most NAFLD patients are
asymptomatic and have normal transaminases [109].
6.2 Prevalence
NAFLD affects up to one third of the population worldwide, and its incidence is
increasing rapidly because of the epidemics of obesity and T2DM [111]. Many
different definitions of MetS, and the many methods of diagnosing NAFLD, make it
challenging to estimate the coexistence of the two disorders [109]. The prevalence
of NAFLD in subjects with MetS has been reported to increase 4-fold when
compared with those without the disease and 35% of NAFLD subjects have been
reported to have MetS [109, 112]. Each of the key components of MetS, insulin
resistance, in particular, associates strongly with NAFLD [113].
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6.3 Pathophysiology of NAFLD and relationship with MetS
Liver is a key organ in the control of carbohydrate and lipid metabolism [5]. In
response to the energy demand of the body, liver releases substrates in the fasting
period and stores glucose in hepatic glycogen and fatty acids in TGs postprandially
under the regulation of insulin [114]. In the liver, two of the key components of
MetS are produced; fasting plasma glucose and very low-density lipoprotein
(VLDL) which contains most of the TGs present in serum [109]. In patients with
NAFLD, the ability of insulin to normally suppress production of glucose and VLDL
is impaired.
The excess accumulation of TG in the cytoplasm of hepatocytes is the hallmark
of NAFLD [115]. This results from an imbalance between lipid acquisition and
disposal [115]. In NAFLD, both processes are increased [116]. Sources of lipids
contributing to fatty liver include FFA released into the circulation from peripheral
adipose tissue, dietary fatty acids from intestinal chylomicrons, and lipids
synthesized in the liver by de novo lipogenesis. Lipids are cleared from the liver
mainly through either mitochondrial fatty acid oxidation or through secretion as a
component of VLDL particles [115].
Overeating, especially of excess simple sugars, and physical inactivity
predispose to both NAFLD and MetS [109]. De-novo lipogenesis, which is increased
up-to three-fold in patients with NAFLD, converts simple sugars to fat in the liver
[109]. In obesity, excess FFAs can enter the liver through the portal circulation
[115]. Increased levels of hepatic FFAs induce increased lipid synthesis and
gluconeogenesis. In patients with NAFLD or MetS, ability of insulin to inhibit
glucose production is impaired, resulting in mild hyperglycemia, which stimulates
insulin secretion resulting in hyperinsulinemia [109]. Furthermore, insulin
resistance leads to failure of insulin to suppress both lipolysis and production of
triglyceride-rich VLDL particles from the liver. Overproduction of large
triglyceride-rich VLDL particles is a major contributory mechanism underlying the
increase in serum TGs in patients with MetS and NAFLD [109]. This not only leads
to lowering of HDL cholesterol but also to generation of small, highly atherogenic
LDL particles.
Additionally, numerous other mechanisms (many of them also MetS-linked)
contribute to the development of NAFLD. They include imbalance of adipokine
production, overactivation of inflammatory chemokines and cytokines, various
genetic factors, and disturbances in immune system and gut microbiome [116].
NAFLD is thus a complex disease arising from interactions between genetic and
environmental factors and having a close relationship with MetS. NASH, which is
the more severe form of the disease, is characterized by steatosis, hepatic
inflammation, and hepatocellular ballooning and may include varying degrees of
fibrosis [115].
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6.4 Quantitative imaging of liver fat
6.4.1 Introduction
Traditionally, NAFLD or hepatic steatosis has been diagnosed based on histology
obtained from liver biopsy with the definition of >5–10% of hepatocytes being fatty
[6, 109]. However, modern MR techniques provide assessment of hepatic TG
content non-invasively with lower sampling error (Fig. 3) [6].
6.4.2 Hepatic 1H-magnetic resonance spectroscopy
The current gold standard to quantify hepatic TG content in vivo is 1H-MRS [6]. It is
the best technique to detect small amounts of fat. Commonly cited definition for
NAFLD by 1H-MRS is liver fat content ≥5.56%, given as weight fraction, which
corresponds to about 10% of liver fat histologically [109, 117].
The same basic principles as earlier presented regarding cardiac 1H-MRS can
generally be applied to hepatic 1H-MRS. Different from cardiac MRS, liver MRS may
be performed with or without respiratory triggering [100]. A limitation of the
technique is the variability of fat distribution throughout the liver [100]. Therefore,
a single MRS measurement is not necessarily representative of the entire liver.
However, T1-weighted in-phase and opposed-phase images may be used to
recognize uneven liver fat distribution and aid in voxel positioning. Large vascular
structures, bile ducts and focal lesions must be avoided when positioning the voxel
of interest. Small voxel size may increase the risk for sampling error. However, the
voxel size is typically at least two orders of magnitude larger compared to size of a
liver biopsy sample.
Figure 3. Liver spectra
of three subjects with
varying degrees of
hepatic steatosis.
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6.4.3 Other imaging techniques
Ultrasound is the most commonly used and most widely available noninvasive
technique for detection of hepatic fat [118]. Steatotic liver demonstrates increased
scatter and attenuation of sound waves compared with normal liver and produces
characteristic pattern of hyperintense liver combined with blurry hepatic vessels
and poor resolution of the diaphragm. The use of ultrasound is limited by poor
penetration in obese individuals and lack of quantitative appliances, leading to
great operator dependence and low sensitivity. However, in a recent study,
subjective qualitative evaluation (4-point scale) of liver echogenicity was reported
to have a relatively good correlation with 1H-MRS measurement [119].
CT can be used for rapid assessment to quantify liver fat [118]. Degree of liver
TG content may be estimated with attenuation values derived from CT used to
estimate density. However, because scanning parameters such as voltage, tube
current, and pitch and patient parameters such as BMI and the presence or absence
of iron, iodinated contrast agents, or other substances vary from patient to patient,
standardized quantitative measurement of steatosis is difficult [119]. Furthermore,
CT requires exposure to ionizing radiation and for mild liver steatosis, sensitivity is
limited [118, 119]. Dual-energy CT does not give added value as compared to mono-
energetic CT in quantifying liver steatosis [119].
Recently, Dixon MRI techniques leveraging the difference between in-phase
and out-of-phase water and fat signals have also been used in quantification of
hepatic steatosis [6]. It enables the measurement of fat fraction relative to water
content pixel-by-pixel, and the inhomogeneity of fatty infiltration may be visualized
with color coded maps. The results are promising and comparable to 1H-MRS as
long as important confounding factors such as T1 bias, noise bias, T2* effects,
spectral modeling of fat, and eddy currents have been addressed [119].
6.5 Association of NAFLD with CVD and cardiac function
NAFLD and MetS have significant overlap including the spectrum of diseases they
predict [109]. MetS is an important predictor of NAFLD and NASH. NAFLD also
predicts both T2DM and CVD. Although abdominal obesity is associated with
NAFLD and MetS, whether visceral fat is causal or correlative of these disorders is
controversial [5]. Emerging evidence suggests that NAFLD may be a CVD risk factor
[111].
Many cross-sectional studies have shown that patients with NAFLD have an
increased rate of CAD at coronary angiography as well as coronary artery calcium
score detected by CT, independently of traditional cardiovascular risk factors [120].
In addition, relationship between the grade of NAFLD and the angiographic severity
of CAD has been reported [120]. Several studies have reported that NAFLD,
diagnosed with imaging techniques, is associated with an increased risk of fatal and
non-fatal CVD events, independently of multiple cardiometabolic risk factors [120].
Furthermore, the severity of NAFLD is associated with higher risk of adverse CVD
outcomes. NAFLD has also been associated with elevated risk of AF [120]. In a study
of nearly 1 000 subjects with a long follow-up time, NAFLD was associated with an
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approximately twofold increased risk of incident AF, independently of multiple
confounding factors [121].
In echocardiographic studies, subclinical early LV diastolic dysfunction has
been shown to associate with NAFLD in nondiabetic [122, 123] and in T2DM [124]
subjects. MRS studies published on cardiac function in NAFLD have been limited
and the results are controversial. Hepatic fat content and myocardial insulin
resistance were associated in T2DM men in a study where LV function and
morphology were not examined [125]. In men with uncomplicated T2DM, patients
with increased intrahepatic fat content had reduced myocardial perfusion and
lower myocardial phosphocreatine (PCr)/ATP ratio but similar LV function and
morphology [126]. Analogously, nondiabetic men with increased intrahepatic fat
content were reported to have impaired LV energy metabolism despite normal LV
morphology and function [127]. Conversely, in a recent study, NAFLD did not affect
PCr/ATP ratio or LV diastolic function [128].
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AIMS OF THE STUDY
1. To explore components of cardiac adiposity and their relationship to intra-
abdominal ectopic fat deposits and cardiometabolic risk factors in MetS (I).
2. To investigate whether LV diastolic function is impaired in MetS, and to
examine how cardiac adiposity is related to the hypothesized LV diastolic
dysfunction (II).
3. To assess the relationship of different ectopic fat depots on LV structure
and function in subjects with NAFLD and to investigate the role of hepatic
fat content on cardiac steatosis (III).
4. To investigate LA structure and function in MetS, and to examine the role
of ectopic fat depots and cardiometabolic risk factors on LA dysfunction
(IV).
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METHODS
Study I II III IV
Method Study object Subjects (n) 77 75 75 73
CMR LV size and systolic function X X X X
LV diastolic function X X
LA size and function X
1H-MRS Myocardial TG content X X X X
Hepatic TG content X X X
MRI Epi/pericardial fat X X X X
Subcutaneous and visceral fat X X X
Table 1. Fat quantification methods and study objects.
1 Study design and subjects
ublications I-IV are based on the data of Cardiac steatosis research project,
a collaboration of HUS Medical Imaging Center (Radiology) and Heart and
Lung Center (Cardiology), Helsinki University Hospital, and Diabetes and
Obesity Research Program, University of Helsinki. The project was
conceived in 2009 to primarily examine myocardial TG content as a new potential
cardiometabolic risk marker. The study design is cross-sectional.
Study subjects aged 18 to 69 were recruited by advertisements in local
newspapers. As the hormonal status and use of contraceptives modify lipid
metabolism in women, only men were recruited. The study design is summarized
and the rates of drop out at each stage are shown in study II, Fig. 1. The final study
population comprised 77 (Study I), 75 (II-III) or 73 (IV) Finnish men of Caucasian
ethnicity. Differences of subject count in studies I-IV were due to variation of
available CMR data of interest.
T2DM related effects on CVD distinct from those of the underlying obesity and
MetS. Therefore, T2DM (based on a 2-h oral glucose tolerance test or antidiabetic
medical treatment) was part of the exclusion criteria. Stable hypertension treated
with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers,
low-dose diuretics, calcium channel blocker or selective beta blockers was allowed
but subjects with untreated hypertension (blood pressure above 160/95 mmHg)
were excluded due to possible confounding effect on cardiac function. Other
exclusion criteria from the study included the following: known presence of or
medical treatment for CAD, previous myocardial infarction, cardiomyopathy, sinus-
or atrioventricular node dysfunction, asthma or chronic pulmonary obstructive
disease; other known relevant chronic disease based on medical history, physical
examination, and standard laboratory tests (blood counts, creatinine, aspartate
aminotransferase, alanine aminotransferase, thyroid-stimulating hormone); and
significant alcohol consumption (more than 20 grams per day). Due to common use
in primary prevention, statins were allowed.  Exclusion criteria included, however,
P
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treatment with other lipid lowering therapy (e.g. fibrates). Smoking and up to 4-
time upper limit of normal (70 U/L) elevated liver enzymes (alanine
aminotransferase) were allowed. Five subjects were receiving medications for
hypertension and five subjects received statins for dyslipidemia.
For the studies I, II and IV, subjects were divided into two groups based on
cardiometabolic risk factors: those with MetS and those without MetS. To qualify
for the MetS group, subjects must have waist circumference ≥ 94 cm in addition to
two or more abnormal findings according to the harmonized definition of MetS
[25]. The other subjects were classified as subjects without MetS. Subjects with
waist circumference ≥94 cm without having additional MetS criteria and subjects
with waist circumference <94 cm presenting with abnormal lipid profile were
excluded. For the Study III, to explore the role of liver fat, we categorized the
subjects into tertiles based on hepatic TG content: group 1 (n=24): low; group 2
(n=26): moderate; and group 3 (n=25): high hepatic TG.
1.1 Ethical statement
The Ethics Committee of the Department of Medicine, Hospital District of Helsinki
and Uusimaa approved the study. Each subject provided written informed consent.
2 Demographic variables and biochemical investigations
Body mass index (BMI) was calculated by dividing weight in kilograms by the
square of the height in meters (kg/m2). Waist circumference was measured in the
horizontal position at a level midway between the lower rib lateral margin and the
iliac crest. Blood pressure was recorded as an average of five measurements using
a BPM-200 monitor (Quick Medical, WA, USA) obtained in the sitting position after
a 5 min rest. The subjects were classified as present, past, or non-smokers.
Blood samples were collected after an overnight fast. Total serum cholesterol,
TGs, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol,
FFAs, apolipoprotein A-I, apolipoprotein B, and high-sensitivity C-reactive protein
were measured by Konelab analyzer 60i with Konelab TM kits (both from Thermo
Fisher Scientific, Finland). The concentration of low-density lipoprotein cholesterol
was derived from the Friedewald formula [129]. Measurement of aspartate
aminotransferase, alanine aminotransferase, creatinine, N-terminal pro-brain
natriuretic peptide, and thyroid-stimulating hormone were performed using
standard laboratory techniques. Fasting and postload glucose were assessed by the
hexokinase method (Gluco-quant, Roche Diagnostics, Basel, Switzerland) using
either a Hitachi 917 or Modular analyzer (both from Hitachi Ltd, Tokyo, Japan).
Serum insulin concentration was determined by double-antibody
radioimmunoassay (Pharmacia RIA kit, Pharmacia, Uppsala, Sweden). The insulin-
resistance homeostasis model assessment (HOMA-IR) index was calculated by
using the formula: (fasting plasma glucose x fasting plasma insulin)/22.5 [130].
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3 Cardiac imaging
3.1 Cardiac magnetic resonance imaging protocol
Cardiac MR images were acquired using a 1.5 T imager (Magnetom Avanto;
Siemens, Erlangen, Germany) subject lying at rest in supine position. We used a
multi-channel body coil for reception. Cine series were acquired in 4-chamber, 2-
chamber, 3-chamber, and LV short axis orientations during breath hold using a
retrospectively electrocardiographically gated steady state free precession
gradient echo sequence [131]. A stack of short axis cine series (typically 12 slices)
was obtained covering the LV from base to apex with typical imaging parameters
of repetition time 50 ms, echo time 1.18 ms, flip angle 69 degrees, matrix 186 × 220,
field of view 355 × 420 mm, slice thickness 8 mm, gap 2 mm, and temporal
resolution 32–53 ms.  Three-chamber oriented cine images were obtained with
typical imaging parameters of repetition time 45 ms, echo time 1.05 ms, flip angle
64 degrees, matrix 156 x 192, field of view 300 × 380 mm, slice thickness 8 mm,
and temporal resolution 44–50 ms.
3.2 Left ventricular analysis
Dedicated post-processing software (Argus; Siemens Medical Solutions, Erlangen,
Germany) was used to perform a volumetric analysis of the LV. LV ejection fraction,
mass, EDV, end-systolic volume (ESV), and stroke volume (SV) were measured, and
both volume parameters and mass were reported as indexed to the subject’s body
surface area (BSA). An LV mass-to-volume ratio was calculated by dividing the LV
mass by EDV (II). An LV global function index (LVGFI) (II) was calculated from the
following formula: LVGFI = [LVSV/((LVEDV+LVESV)/2 + LV mass/1.05)]x100
[132].
Segmentation of endocardial borders was performed for all LV short-axis slices
across all temporal phases to assess the time course of global volumetric filling. An
LV early diastolic peak filling rate (PFR) was obtained from the LV volume versus
time curve (II-III). LV EDV normalized values of PFR (PFR/LVEDV) were also
calculated. The LV filling curve was visually inspected to identify the plateau
between the early diastole caused by ventricular relaxation and the late diastole,
the result of atrial contraction (II, Fig. 2A). The resulting diastolic plateau volume
was divided by the EDV and the resulting percentile was reported as the ratio of
early diastole. The physiological basis for measuring this index is that in the first
phase of diastolic dysfunction, the proportion of LV filling in the early phase of
diastole is reduced, and the contribution of left atrial contraction to LV filling is
increased [62]. Diastolic dysfunction can be seen in LV volume kinetics as a
depression of the diastolic plateau and as a shift from left to right in early diastole
due to suppressed PFR (II, Fig. 2B).
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3.3 Left atrial analysis
Three-chamber oriented images were used for measuring LA area in a single plane
(IV, supplemental Fig. 2A). All phases of the cine images were inspected, and
minimum and maximum LA area were planimetered using a diagnostic radiologic
workstation (Impax 6 software, Agfa Healthcare, Mortsel, Belgium), and reported
as LA 2D model. LA area measured in 3ch MR image has shown to be a reliable
indicator of LA size [133] but volumetric CMR data based on 3ch images has not
been reported.  For 3D modeling of the LA, we used a prolate ellipsoid model which
is commonly used for estimating LA volume in echocardiographic studies. Volume
of the ellipsoid was calculated according to formula: V = ସ
ଷ
where ,ܾܿܽߨ πab = 3chA,
area measured in the 3ch image, and c =0.5*h, where h equals maximum
craniocaudal diameter of the left atrium in a short axis (SA)-oriented image at the
midline of the LA (IV, supplemental Fig. 2B). Both measurements were done in end-
systolic and end-diastolic images to obtain minimum and maximum LA volumes,
and to calculate EF. Volume parameters are reported also as indexed to the
subject’s body surface area (BSA).
Comparison of LA assessment of 3ch prolate ellipsoid model and traditional
Simpson’s method, considered as gold standard, was performed for a group (n=10)
of study subjects with sufficient data available for both methods. In these subjects,
LA volume was planimetered from a stack of SA cine images with Simpson’s method
using dedicated software (QMass MR v.7.6, Medis Medical Imaging Systems, Leiden,
Netherlands).
3.4 Adenosine stress perfusion magnetic resonance imaging
In participants who fulfilled the criteria for the MetS, we performed adenosine
stress perfusion CMR to exclude myocardial ischemia and scar tissue. The rationale
for this procedure was to exclude the potential interfering effects of CAD-associated
myocardial scar tissue and/or altered cardiac function.
The adenosine stress perfusion MR was carried out in a 3.0 T MR imager
(Verio; Siemens, Erlangen, Germany) according to a standardized protocol [131]
including a first-pass perfusion module performed with a dynamic turbo flash
perfusion sequence with typical imaging parameters of TR/TE/flip angle 199
ms/1.14 ms/12 degrees, matrix 192 x 180, slice thickness 8 mm, gap 20 mm, and a
late gadolinium enhancement module acquired with a phase sensitive inversion
recovery sequence with typical imaging parameters of TR/TE/flip angle 700
ms/1.16 ms/40 degrees, matrix 192 x 192, slice thickness 8 mm and gap 8.8 mm.
Inversion time was set according to TI scout to null the normal myocardium. An
intravenous adenosine infusion of 140 µg/kg/min was administered for five
minutes under continuous ECG monitoring. Dynamic perfusion images were
obtained in short axis (three positions) and 2-chamber orientations at four minutes
after the onset of adenosine infusion during injection of 0.1 mmol/kg gadoteric acid
(Dotarem, Guerbet, Villepinte, France) at a rate of 5 ml/s.  Late gadolinium
enhancement images were obtained 10 minutes after the administration of
contrast agent in short axis, 2-chamber and 4-chamber orientations. Imaging data
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was visually assessed to exclude any perfusion defects and myocardial late
enhancement.
3.5 Quantification of myocardial triglyceride content
For measuring myocardial triglyceride (TG) content, we performed cardiac 1H-MRS
in a 1.5 T MR imager (Magnetom Avanto; Siemens) using a standard flex-coil for
signal acquisition. A 36×24×10 mm3 voxel was positioned in the interventricular
septum (Fig. 4) using end-systolic cine images in three planes for localization. The
localizer images and spectroscopic data acquisition were double-triggered to end-
exhalation and end-systole, using Prospective Acquisition Correction navigator
echoes (PACE, WIP-sequence, program version B17, Medical Solutions USA Inc,
New York, New York) to control for respiratory movement and electrocardiograph-
derived R wave to control for cardiac pulsation.
A PRESS sequence with echo time of 35 ms and repetition time >3000 ms was
used for spatial localization and data collection. Navigator echoes were collected
from the lung-diaphragm interface and the end-systole triggering was set at about
80% of the resting heart rate of the subject. The spectra were collected with and
without water suppression, using 32 and 4 acquisitions, respectively, and analyzed
with jMRUI v3.0 software (http://www.jmrui.eu) [134] using the AMARES
algorithm [135] to determine water (4.7 ppm), methylene (1.3 ppm) and methyl
(0.9 ppm) resonance areas (III, Fig. 1A). Myocardial TG content was expressed as a
ratio of fat to water (%). We did not correct for methylene T2 relaxation due to lack
of reliable data for cardiac application.
Figure 4. Four-chamber oriented MR image of voxel positioning in the ventricular
septum of the heart.
M e t h o d s | 41
3.6 Quantification of epicardial and pericardial fat
Segmenting the epicardial and pericardial fat planes is very time consuming
and standardized measurement is challenging due to anatomical variety. In our
preliminary data, epicardial and pericardial fat areas measured in a single 4-
chamber view slice showed good correlation with epicardial and pericardial fat
volumes measured with conventional Simpson method covering both right and left
ventricles in a stack of short axis image slices (N=6, r=0.895, p <0.02). Therefore,
we used epicardial and pericardial adipose tissue areas measured in a 4-chamber
oriented image to estimate the amount of epicardial and pericardial fat, a method
also used by others [106].
We inspected all phases of the cine images and performed the measurements
in the single end-diastolic image using a standard radiologic workstation (Impax
5.5 software, Agfa Healthcare, Mortsel, Belgium). The areas of high intensity fat
layers between the myocardium and the visceral pericardium (epicardial fat) and
outside the parietal pericardium (pericardial fat) were measured (I, Fig. 1). Intra-
thoracic adipose tissue outside the pericardium in the particular slice was included
to the value of pericardial fat. A stack of short-axis oriented end-diastolic T1-
weighted turbo spin echo images (Fig. 1, Review of the literature, Chapter 5.2) was
also obtained (with typical imaging parameters of: repetition time 1050 ms, echo
time 29 ms, flip angle 180 degrees, matrix 256 × 256, slice thickness 6 mm, and gap
1.5 mm), and they were additionally used to aid in epi- and pericardial fat
separation as well as in water and fat separation, once needed. Intra- and inter-
observer variability of epicardial and pericardial fat quantification was evaluated
by two radiologists on separate occasions by the measurement of 20 (10 MetS and
10 without MetS) randomly selected study subjects.
4 Abdominal imaging
4.1 Quantification of hepatic triglyceride content
For measuring hepatic TG content, we performed 1H-MRS in a 1.5 T MR imager
(Magnetom Avanto; Siemens) using a standard body coil for signal reception. A
25×25×25 mm3 voxel was placed in the middle of the right liver lobe avoiding large
vessels and intrahepatic bile ducts (Fig. 5). Unsuppressed PRESS sequence with
echo time of 30 ms, repetition time of 3000 ms and 4 averaged acquisitions was
used to collect liver spectra during free breathing. We analyzed the spectra with
jMRUI v3.0 software [134] and AMARES-algorithm [135]. Areas of water signal (4.7
ppm) and methylene (1.3 ppm) were determined using a line-fitting procedure (III,
Fig. 1B). Signal intensities were corrected for T2 decay and hepatic TG content was
calculated as methylene/(water + methylene) signal area x 100, and the values
were further converted to mass fractions [136].
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4.2 Quantification of subcutaneous and visceral fat
Distributions of VAT and SAT were determined using a stack of 16 T1-weighted
trans-axial 2-dimensional multislice spoiled gradient echo images acquired from a
region extending from 8 cm above to 8 cm below the fourth and fifth lumbar
intervertebral disks [137], using a standard body coil for image acquisition. MR
images were analyzed using SliceOmatic v4.3 segmentation software. The areas of
SAT (shown green in Fig. 6) and VAT (shown red in Fig. 6) were measured for each
slice using a region-growing routine. The results were expressed as total volumes
of SAT and VAT. We also calculated the VAT/SAT ratio as a metric of abdominal fat
distribution [138].
Figure 5. Axial (left) and coronal (right) MR images of voxel positioning in the right
lobe of the liver.
Figure 6. Segmentation of the subcutaneous (green) and visceral (red) fat.
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5 Statistical analyses
We performed all statistical analyses with IBM SPSS Statistics (versions 19.0-24.0,
IBM Corp., Armonk, NY, USA). Normality of continuous variables was analyzed by
the Kolmogorov-Smirnov test. Logarithmic, square root or reciprocal
transformation of variables was performed, if necessary. Data are presented as
frequencies or percentages for categorical variables, as means ± SD for normally
distributed continuous variables, and as medians (range) for skewed variables.
Between-group differences (I, II, IV) were assessed by the Mann–Whitney U test,
unpaired t-test, or the χ2 test, as appropriate. For analysis of three groups (III),
differences were examined by 1-way ANOVA, and P values for pairwise between
groups differences were adjusted for multiple comparison in a post hoc Bonferroni
t test. ANCOVA was applied to compare the means or medians of LV dimensions and
function with adjustment for age. Levene’s test was used to assess homogeneity of
variances. If variances were not homogenous across the groups, nonparametric
Kruskal–Wallis test was used.
For correlation analyses, Pearson or Spearman correlation coefficient was
used depending on distribution of values. For analyses with distinct adjustments
(i.e. age and smoking), partial correlation or univariable linear regression analyses
were performed. Multivariable stepwise regression analyses were performed to
determine independent predictors of cardiometabolic risk factors, LV diastolic
function, and LA function (I-IV). Details of correlation analyses as well as
univariable linear regression and multivariable regression analyses are described
in each original publication.
Intra- and inter-observer variability of evaluation of epi- and pericardial fat
was assessed via intra-class correlation coefficients (ICC) (II). Absolute agreement
ICCs were calculated via a two-way mixed model for single measures. Three-
chamber-based LA volume assessment and SA-based Simpson’s method were
compared using Pearson correlation and Bland-Altman analysis (IV).
For all analyses, p<0.05 was considered statistically significant.
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RESULTS
Clinical and biochemical characteristics of the study groups (Publications I, II, IV)
linical and biochemical characteristics are summarized in Table 2. Subjects
with MetS (n = 37) were, on average, 7 years older than subjects without
MetS (n = 40) and included more current smokers. As expected, participants
with MetS had greater waist circumference and BMI than controls. Subjects
with MetS had higher fasting serum glucose and insulin, and HOMA-IR index
respectively than control subjects. In the MetS group, 24 subjects had normal
glucose tolerance, 4 had impaired fasting glucose, and 9 had impaired glucose
tolerance. All individuals in the non-MetS group had normal glucose tolerance.
Comparison of the serum lipid profile between the groups showed notable
differences. In subjects with MetS, fasting plasma TGs were elevated on average 3-
fold higher than in the control group. Additionally, higher total cholesterol and LDL,
and lower HDL were observed in the MetS group compared to controls.
Furthermore, systolic and diastolic blood pressure, and Hs-CRP were higher in
subjects with MetS than in controls. NT-proBNP levels were comparable between
the groups.
MetS present MetS absent p
N 37 40
Age (years) 47 ± 6 40 ± 8 <0.001
Current smokers (N, %) 13 (35) 5 (12) 0.019
Body mass index (kg/m2) 30.9 (24.2-42.5) 23.4 (17.6-29.8) <0.001
Waist circumference (cm) 107 (94-135) 87 (71-94) <0.001
Systolic blood pressure (mmHg) 132 ± 14 115 ± 10 <0.001
Diastolic blood pressure (mmHg) 88 ± 9 74 ± 6 <0.001
Total cholesterol (mmol/l) 5.3 ± 0.74 4.4 ± 0.79 <0.001
LDL (mmol/l) 3.3 ± 0.71 2.5 ± 0.66 <0.001
HDL (mmol/l) 1.0 ± 0.26 1.5 ± 0.39 <0.001
TGs (mmol/l) 2.2 (0.65-6.3) 0.78 (0.35-1.6) <0.001
High-sensitivity CRP (mg/l) 1.8 (0.2-11.8) 0.2 (0.0-5.8) <0.001
NT-proBNP (ng/l) 27 (5-151) 23 (5-74) 0.210
fP-ALT (U/l) 39 (20-260) 21 (7-59) <0.001
fP-glucose (mmol/l) 5.8 (4.6-6.9) 5.0 (4.4-6.0) <0.001
fS-insulin (mU/l) 9.3 (3.3-37) 2.9 (0.9-7.7) <0.001
HOMA index 2.6 (0.8-8.0) 0.6 (0.2-2.0) <0.001
Myocardial TG content (%) 0.90 (0.31-2.3) 0.44 (0.14-1.4) <0.001
Epicardial fat (mm2) 838 (385-1750) 520 (251-1130) <0.001
Pericardial fat (mm2) 1905 (615-6130) 562 (66-1580) <0.001
Hepatic TG content (%) 6.59 (0.40-31.7) 0.73 (0.17-4.45) <0.001
VAT (cm3) 3300 (1260-5740) 843 (67-3170) <0.001
SAT (cm3) 4820 (2216-9354) 1770 (284-4020) <0.001
VAT/SAT ratio 0.63 (0.26-1.64) 0.46 (0.13-1.23) 0.001
Data are expressed as means (± SD), medians (range) or as frequencies (%). MetS, metabolic syndrome; LDL, Low-density
lipoprotein cholesterol; HDL, High-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; ALT, alanine
aminotransferase; HOMA, the homeostasis model assessment insulin resistance; VAT, visceral adipose tissue; SAT,
subcutaneous adipose tissue.
C
Table 2. Summary of clinical and biochemical characteristics and fat compartments.
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MetS is highly associated with ectopic fat accumulation (I)
Measurements of ectopic fat deposits are shown in Table 2. Fig. 7 shows examples
of cardiac and hepatic spectra. In participants with MetS, hepatic TG content was
on average 9-fold higher than in controls (Fig. 8). Visceral and subcutaneous fat
masses were higher in the group with MetS being increased by 3.9-fold and 2.7-fold
compared to the group without MetS. Myocardial TG content was on average twice
higher in MetS subjects. Similarly, epicardial and pericardial fat were markedly
higher in subjects with MetS compared with subjects without MetS.
Visceral obesity is linked with hepatic and cardiac adiposity (I)
Univariate correlation analyses between ectopic fat depots and different clinical
study parameters adjusted for age and smoking showed that VAT correlated with
Figure 7. Cardiac and hepatic spectra from 2 subjects: one with low (A) myocardial
and (B) hepatocellular triglyceride (HCTG) contents, and the other with high (C)
myocardial (MCTG) and (D) HCTG contents. Shaded areas have been zoomed above
by factors 150, 30, and 25 for spectra A, B, and C, respectively. Reprinted with the
publisher’s permission from Publication III.
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hepatic TG content as well as with waist circumference and BMI (Fig. 9). Myocardial
TG content, epicardial fat, and pericardial fat correlated with SAT and VAT, and
hepatic TG content and the correlations seemed to be stronger with VAT than with
SAT or hepatic TG content. Myocardial TG content, epicardial fat, pericardial fat,
hepatic TG content, and VAT showed significant correlations with waist
circumference, BMI, HDL, TGs, plasma insulin, and the HOMA index. Hs-CRP was
linked to epicardial and VAT. Epicardial and pericardial fat were highly
intercorrelated, however, neither correlated with myocardial TG content.
Visceral fat is the best independent predictor of cardiometabolic risk factors (I)
We performed stepwise multivariable regression analyses (Publication I, Table 3)
to evaluate the impact of fat depots on individual cardiometabolic risk factors
(serum TGs, HDL, fasting plasma glucose, plasma insulin, the HOMA index, and
systolic and diastolic blood pressure). VAT was an independent predictor of TGs,
HDL, plasma glucose, plasma insulin, and the HOMA index. Age and subcutaneous
fat were independent determinants of systolic and diastolic blood pressure.


































































Figure 8. Comparison of ectopic fat deposits between study groups. All correlations p<0.001.
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LA function and dimensions
LA EF (3D model)
LA EF (2D model)
LA EDV/BSA
LA ESV/BSA
Figure 9. Heatmap visualization of a summary of univariate correlations. Scale indicates
strength of a relationship: red columns indicate positive, blue negative, and white non-
significant correlations. Self-correlations are excluded.
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Reproducibility of fat quantification (II)
Intra-observer reproducibility for epicardial fat measurement in 4-chamber MR
images was high with an intra-class correlation coefficient of 0.97 and 0.99 for
pericardial fat, respectively. Inter-observer reproducibility showed an intra-class
correlation coefficient of 0.91 for epicardial and 0.96 for pericardial fat.
With the aim of testing the repeatability of the cardiac 1H-MRS with WIP-
sequence, we repeated the sequence in five subjects with different degrees of
myocardial TG content. Shim values and measurement parameters were kept
unaltered. The measurements correlated (R2 = 0.9975) with a coefficient of
variation of 9.0%.
MetS associates with concentric LV remodeling and diastolic dysfunction (II)
Results of CMR measurements and analysis of LV function are outlined in Table 3.
BSA- indexed values of LV ESV, EDV, and SV were smaller in the MetS subjects than
in the subjects without MetS. LV volumes were within the normal range in both
study groups, and differences remained significant after adjustment for the amount
of exercise (data not shown). LV ejection fraction was normal in all participants and
analogous between the study groups, indicating preserved systolic LV function. The
BSA-indexed LV mass was also comparable between the groups. The LV mass-to-
volume ratio was greater and the LVGFI lower in the MetS group compared to the
control group, indicating concentric rather than eccentric LV remodeling. Diastolic
dysfunction was associated with MetS as demonstrated by lower LV early diastolic
PFR, PFR/EDV, and ratio of early diastole in subjects with MetS than in the controls
(Fig. 10).
MetS present MetS absent p
N 37 38
LV ejection fraction (%) 61 ± 6 62 ± 4 0.745
LV ESV/BSA (ml/m2) 25 ± 7 32 ± 5 <0.001
LV SV/BSA (ml/m2) 40 ± 8 52 ± 7 <0.001
LV mass/BSA (g/m2) 58 ± 9 62 ± 7 0.190
LV mass/EDV (g/ml) 0.88(0.66-1.32) 0.73 (0.61-0.90) <0.001
LV global functional index (%) 41 (24-51) 44 (35-54) <0.001
LV EDV/BSA (ml/m2) 65 ± 13 84 ± 11 <0.001
LV peak filling rate (ml/s) 471 (238-909) 667 (329-1315) 0.002
LV peak filling rate/LV EDV (s-1) 3.37 (1.89-5.46) 3.75 (2.63-7.23) 0.023
LV early diastole (%) 68 ± 9 78 ± 8 0.001
Data are expressed as means (± SD), medians (range). MetS, metabolic syndrome; LV, left ventricular; ESV,
end-systolic volume; BSA, body surface area; SV, stroke volume; EDV, end-diastolic volume.
Table 3. Summary of left ventricular dimensions and function.
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Figure 10. Comparison of left ventricular diastolic function between study groups.
Accumulation of epicardial and pericardial fat correlates with the degree of
LV diastolic dysfunction (II)
Age-adjusted univariate correlation analysis (Fig. 9) revealed that the amount of
epicardial and pericardial fat was inversely correlated with the parameters of
diastolic function (PFR, PFR/EDV, and ratio of early diastole).  Myocardial TG
content correlated with the ratio of early diastole, but not with PFR. The LV
remodeling index (mass-to-volume ratio) and BSA-indexed EDV, ESV, and SV
correlated with the myocardial TG content, and with pericardial and epicardial fat.
Myocardial TG content is not independently associated with LV diastolic
dysfunction (II)
We used a multivariate correlation analysis (II, Table 4) to further evaluate the
interrelationship between the individual cardiac fat depots and LV diastolic
dysfunction. Age and epicardial and pericardial fat were all independent
determinants of PFR and PFR/EDV. Age and pericardial fat were also independent
predictors of the ratio of early diastole. Interestingly, once the effect of age, waist
circumference, body mass index, blood pressure parameters, and epicardial and
pericardial fat were taken into account, myocardial TG content was not
independently related to any parameter of diastolic dysfunction.
Clinical and biochemical characteristics of the study groups categorized
based on hepatic steatosis (III)
Subjects were categorized into tertiles based on hepatic TG content: group 1: low
(0.17-1.05%); group 2: moderate (1.17-5.16%); and group 3: high (5.45-31.74%)
hepatic TG. Clinical and biochemical characteristics of the study groups are
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waist circumference, heart rate, and systolic and diastolic blood pressures
compared with the other groups. There were more current smokers in individuals
with high liver fat when compared with those with low liver fat. Participants with
high liver fat had hypertriglyceridemia, lower HDL, higher LDL and a high
concentration of apolipoprotein B, as well as elevated glucose and insulin levels and
HOMA-IR, when compared with those with the low liver fat group. FFAs were
comparable among the groups. Myocardial TG was 3-fold higher in the high liver fat
group and 2-fold higher in the moderate liver fat group when compared with that
in the low liver fat group. Furthermore, epicardial and pericardial fat depots were
increased in the high liver fat group when compared with the other groups. As
expected, VAT and SAT increased stepwise from the low to high liver fat group. The
VAT/SAT ratio was comparable in the groups with moderate and high liver fat but







N 24 26 25
Age (years) 38 ± 7 45 ± 8* 47 ± 8* 0.002
BMI (kg/m2) 23.2 (17.6-32.5) 25.8 (19.8-34.1)* 32.2 (25.3-42.5)*† <0.001
Waist circumference (cm) 85.5 (71.0-109) 93.2 (79.0-108) 112 (94.0-135)*† <0.001
Heart rate (bpm) 61 ± 10 61 ± 8 71 ± 14* 0.004
Systolic blood pressure (mmHg) 115 ± 9 123 ± 13 133 ± 16* <0.001
Diastolic blood pressure (mmHg) 75 ± 6 80 ± 10 88 ± 10* <0.001
Total cholesterol (mmol/l) 4.21 ± 0.80 5.08 ± 0.94* 5.10 ± 0.63* <0.001
LDL cholesterol (mmol/l) 2.40 ± 0.69 3.16 ± 0.88* 3.04 ± 0.53* 0.001
HDL cholesterol (mmol/l) 1.47 ± 0.43 1.35 ± 0.40 1.00 ± 0.26*† <0.001
TGs (mmol/l) 0.82 (0.35-1.30) 0.92 (0.41-5.13) 2.50 (0.89-6.26)*† <0.001
Apolipoprotein B (mg/dl) 72 ± 16 94 ± 28* 117 ± 26*† <0.001
Fasting FFAs (µmol/l) 429 ± 209 529 ± 191 500 ± 163 0.175
fP-ALT (U/l) 24 (7-59) 25 (8-98) 38 (20-259)*† <0.001
fP-glucose (mmol/l) 5.0 (4.5-5.9) 5.3 (4.4-6.5) 5.8 (4.9-6.9)*† <0.001
fS-insulin (mU/l) 2.5 (0.9-5.7) 4.3 (1.3-22.5)* 11.6 (3.3-36.9)*† <0.001
HOMA-IR index 0.6 (0.2-1.5) 1.0 (0.3-5.1)* 3.0 (0.8-8.0)*† <0.001
Myocardial TG content (%) 0.38 (0.14-1.00) 0.72 (0.21-1.39)* 1.11 (0.35-2.33)*† <0.001
Epicardial fat (mm2) 489 (283-807) 692 (251-1750)* 930 (565-1666)*† <0.001
Pericardial fat (mm2) 527 (66-1280) 1170 (261-6130)* 1940 (615-4631)*† <0.001
Visceral fat (cm3) 521 (67-2280) 1890 (217-4180)* 3910 (1257-5740)*† <0.001
Subcutaneous fat (cm3) 1460 (381-880) 2840 (284-6200)* 5050 (2216-9350)*† <0.001
VAT/SAT ratio 0.38 (0.13-1.09) 0.60 (0.28-1.31) * 0.65 (0.38-1.64)* <0.001
LV ejection fraction (%) 63 ± 4 61 ± 4 60 ± 7 0.172
LV ESV/BSA (ml/m2) 32 ± 7 29 ± 6 26 ± 6 0.123
LV SV/BSA (ml/m2) 53 ± 9 45 ± 7 39 ± 9* <0.001
LV EDV/BSA (ml/m2) 85 ± 14 74 ± 13 65 ± 13* 0.001
LV mass /BSA (g/m2) 64 ± 7 59 ± 8 58 ± 9 0.211
Peak filling rate (ml/s) 699 (459-1315) 505 (329-980) 471 (238-909)* 0.005
PFR/LV EDV (s-1) 4.07 (3.03-7.23) 3.48 (2.56-5.58) 3.17 (1.89-5.46)* 0.003
LV early diastole (%) 78 ± 9 73 ± 10 68±9* 0.033
Data are expressed as means (±SD) or medians (range).
P values are presented for ANOVA or ANCOVA between hepatic TG content groups.
*Differs significantly (P<0.05) from hepatic TG content group low
†Differs signi icantly (P<0.05) from hepatic TG content group moderate. Tests are Bonferroni adjusted for
multiple comparisons.
Table 4. Summary of characteristics and measurements categorized based on hepatic fat.
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High hepatic TG content and high amount of visceral fat associate with LV
diastolic dysfunction (III)
In age-adjusted analyses, parameters of LV diastolic function showed a stepwise
decrease over tertiles of liver fat (Table 4). PFR, PFR/LVEDV, and ratio of LV early
diastole differed significantly between the high and low liver fat groups. All
parameters behaved similarly when the subjects were categorized based on VAT
(III, Fig. 2; Tables 1 and 2 in the Data Supplement). This was due to high
interrelationship of hepatic TG and VAT (r=0.832; P<0.001). LV EF, LV mass, and
LV ESV/BSA were similar between liver fat tertiles. Subjects with high liver fat had
decreased LV EDV and SV indexed to BSA compared with low liver fat subjects.
In univariate correlation analyses adjusted for age, BMI, smoking, heart rate,
and blood pressure parameters (III, Table 3), LV PFR and PFR/LVEDV were
inversely correlated with hepatic TG and VAT demonstrating LV diastolic
dysfunction. Furthermore, PFR was inversely correlated with the VAT/SAT ratio.
Hepatic steatosis and visceral fat are strong predictors of LV diastolic
dysfunction (III)
We performed multivariable regression analyses with diastolic function
parameters as independent variables and different ectopic fat depots as dependent
variables (III, Table 4). Due to high interrelationship, visceral fat and liver fat were
not forced into same model. Analyses were adjusted for age, BMI, waist
circumference, blood pressure parameters, heart rate, smoking status, TGs, HDL,
and fasting plasma glucose. The analyses revealed that hepatic TG was the best
predictor of LV PFR and PFR/LVEDV (model 1). The results of multivariable
analyses were closely similar when hepatic TG was replaced with VAT (model 2).
When the effect of hepatic or visceral fat was considered, there was no significant
association between myocardial TG and diastolic parameters. However, pericardial
fat appeared to be the best predictor of ratio of LV early diastole.
MetS associates with LA dysfunction (IV)
LA CMR data is outlined in Table 5. LA ED (maximum) areas (2D model) and
volumes (3D model) were comparable between study groups. LA ES (minimum)
areas and volumes were larger in the MetS group than in control group. However,
BSA-indexed LA ED or ES areas (2D model) or volumes (3D model) did not differ
between groups. In both 2D and 3D models, LA EF was lower in the MetS group
than in the group without MetS indicating LA dysfunction.
LA dysfunction is associated with several contributory factors of MetS (IV)
In both 2D and 3D models of LA EF, age, waist circumference, BMI, fasting plasma
glucose, fasting serum insulin, HOMA-IR index, hs-CRP, hepatic TG content, VAT,
and SAT correlated inversely with LA EF and HDL correlated positively with LA EF
(IV, Table 2 and Fig. 1). In the 3D LA model, correlations of myocardial TG content,
epicardial and pericardial fat with LA EF were not significant (Fig. 9).
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Univariate linear regression analysis was performed for the 3D model of LA EF
(IV, Table 3). In age-adjusted linear regression model, regression coefficients with
LA EF and waist circumference, BMI, SAT, VAT, fasting serum insulin, HOMA-IR
index, and HDL were significant. Negative correlation of LA EF and glucose, hs-CRP,
and hepatic TG content existed but these did not remain significant after adjusting
for age.
MetS present MetS absent p
N 33 40
2D model
LA 3ch Area EF (%) 32.1 ± 6.3 36.8 ± 8.4 0.008
LA 3ch Area ED (mm2) 2230 ± 470 1980 ± 320 0.012
LA 3ch Area ED/BSA (10-4) 10.2 ± 2.0 10.1 ± 1.6 0.786
LA 3ch Area ES (mm2) 1520 ± 350 1250 ± 270 0.001
LA 3ch Area ES/BSA (10-4) 6.9 ± 1.5 6.3 ± 1.3 0.095
3D model
LA EF (%) 44 ± 7.7 49 ± 8.6 0.013
LA EDV (ml) 86 ± 23 79 ± 17 0.160
LA EDV/BSA (ml/m2) 39 ± 9.7 40 ± 8.5 0.638
LA ESV (ml) 48 ± 15 40 ± 11 0.015
LA ESV/BSA (ml/m2) 22 ± 6.5 20 ± 5.1 0.285
Data are expressed as means (± SD). MetS, metabolic syndrome; LA, left atrial; EF, ejection fraction; EDV, end-
diastolic volume; ESV, end-systolic volume; BSA, body surface area.
Visceral fat is the best predictor of LA dysfunction (IV)
Stepwise multivariable regression analysis was performed to further examine the
relationship of ectopic fat depots and LA EF (IV, Table 4). It revealed that VAT
followed by SAT were the best predictors of reduced LA EF when age, BMI, and
hepatic TG content were taken into account.
Three-chamber prolate ellipsoid method is a feasible method for measuring
LA volume (IV)
Comparison of LA volume assessment by 3ch prolate ellipsoid method and SA
volumetric method was performed. LA measurements obtained with 3ch-based
volume assessment correlated highly (r = 0.97 for EDV, r = 0.90 for ESV, and r = 0.93
for EF, p<0.001 for all correlations) with volumetric SA-based Simpson’s method.
Bland-Altman analysis (IV, supplemental Fig. 3) demonstrated mean difference of
LA EDV -1.06 ±3.60 ml, LA ESV -1.54 ±3.12 ml and EF 0.83 ±3.16 %.
Table 5. Summary of left atrial dimensions and function.
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DISCUSSION
n this study, we used MRI and 1H-MRS to examine cardiac steatosis by
quantifying all three cardiac fat stores and cardiac function and related these
data to intra-abdominal fat depots, including liver fat, in a relatively large
nondiabetic group of abdominally obese men free of clinical CVD. The definition
of MetS was used as a tool to identify obese subjects at high cardiometabolic risk in
this study.
Ectopic fat deposition in MetS
In MetS, all examined ectopic fat depots were increased compared to controls. We
found an ~2-fold elevation in myocardial and epicardial fat, and an ~3-fold
elevation in pericardial fat depot in subjects with MetS. Myocardial TG content
correlated with visceral fat, hepatic TG content, and multiple parameters of overall
obesity. The association of multiple cardiometabolic risk factors with myocardial
TG content, pericardial fat, and epicardial fat agrees with previous studies [77, 139].
Most studies have measured either pericardial or epicardial fat depots because
their quantification is technically easier than that of lipids in cardiomyocytes, the
latter requesting a more sophisticated technique. Overall, both pericardial and
epicardial fat depots associate with the amount of visceral fat that is increased in
obesity, subjects with MetS, impaired glucose tolerance, and subjects with type 2
diabetes mellitus [139]. Notably, these 3 cardiac sites differ in their capacity to
accumulate fat, with the pericardial site having the greatest capacity and
cardiomyocytes having the lowest capacity. Thus, growing of cardiac fat depots in
men with MetS in context of visceral adiposity is an expected finding.
Our data confirm and expand the results by Gaborit et al. [140], who reported
that epicardial fat volume and myocardial TG content were increased in individuals
with MetS. Notably, the 2 studies show differences in participants because the
cohort of Gaborit et al. [140] exhibited extreme obesity (BMI range, 33 to 52
kg/m2), including only 18 subjects with MetS, and reported no data on hepatic TG
content. Furthermore, our results expand previous observations of increased
myocardial lipid accumulation in insulin-resistant states in subjects with impaired
glucose tolerance and T2DM to abdominally obese men with cardiometabolic risk
factors [84-86]. We showed that visceral fat was an independent predictor of TGs,
HDL, and measures of glucose metabolism, on the contrary to the subcutaneous fat
which was related to blood pressure parameters. The data highlight that visceral
adiposity lies at the root of the systemic effects linked to ectopic fat depots
quantified by MR technology, as proposed also by Després [5].
The inefficient storage capacity of SAT mass combined with extra caloric intake
results in excessive flow of FFAs into the systemic circulation, driving the overload
of FFAs into ectopic fat depots [5]. In this concept, expansion of visceral, pericardial,
and epicardial fat depots represent visceral components and the preferential places
to store excess dietary fats. Our data support the concept that visceral fat depot is
the priority site for excess fat storage. Moreover, pericardial and epicardial fat
depots are interrelated with visceral fat and good markers of ectopic fat deposition.
I
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The constellation of these 3 fat depots is linked to the development of the
cardiometabolic risk profile, including disturbances of both glucose and lipid
metabolism.
The liver plays a central role in controlling lipid and FFA metabolism. Notably,
the liver is exposed to first-pass FFAs from VAT. Recognizing the strong correlation
between VAT and hepatic TG content, it was not surprising that hepatic TG content
showed a correlation with myocardial TG content. Likewise, McGavock et al.
reported a modest correlation between hepatic and myocardial TG content [86].
LV diastolic dysfunction and concentric remodeling in MetS
In our study, MetS was strongly associated with LV diastolic dysfunction, as
demonstrated by lowered LV early diastolic PFR and ratio of early diastole. In
earlier studies, reduced PFR in insulin-resistant obese women and in T2DM
patients have been reported [87, 141]. Rider et al. reported similar findings in a
female-dominant gender-mixed cohort consisting of markedly obese subjects (BMI
38.7) with unknown status of MetS [142]. Thus, our study adds to previous
knowledge on the association between MetS and LV diastolic dysfunction in non-
diabetic male subjects with moderately increased BMI. Additionally, we showed
that LV diastolic function gradually decreases across tertiles of increasing VAT and
hepatic TG content. Our results give further support to the role of cardiometabolic
effects of visceral obesity in the development of obesity-associated LV diastolic
dysfunction. Consistent with our findings, visceral obesity, MetS, and T2DM have
been related to LV diastolic dysfunction as assessed by feature-tracking CMR in two
latter publications. 1) Rayner et al. demonstrated that increasing visceral fat
associates with lower peak diastolic strain rate [143]. 2) Ladeiras-Lopes et al.,
reported that subjects with MetS or T2DM showed lower end-diastolic strain rate
and higher strain rate index than individuals without MetS [144].
The LV mass was similar in our two study groups, but LV concentric
remodeling was present only in subjects with MetS. Concentric LV remodeling has
been associated with abdominal obesity and is considered as an early sign of
obesity-related cardiac remodeling before the development of LV hypertrophy
[58]. Furthermore, LVGFI has recently been introduced as a novel method to
integrate LV structure with global function [132]. An LVGFI value of <37% was
associated with a significant risk of cardiovascular events. In our study population,
LVGFI was significantly lower in the MetS patients than in the subjects without
MetS, also supporting the tenet that the nature of cardiac remodeling is concentric
rather than eccentric in MetS.
Further support to these findings has been published recently. Neeland et al.
reported that increased central adiposity was independently associated with
concentric LV remodeling as measured by increased LV wall thickness, increased
LV mass/volume ratio, and smaller LV EDV [145]. Moreover, overall body fat was
associated with higher cardiac output and lower systemic vascular resistance,
however, this association was not uniform across fat depots. In contrast, a
significantly lower cardiac output and higher systemic vascular resistance
associated with visceral fat. This was in line with our findings where stroke volume
was lower in the MetS group than in controls. They also reported that lower body
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(gluteal-femoral) adiposity was associated with eccentric remodeling (increased
LV EDV with reduced LV mass, concentricity, and wall thickness) and a higher
cardiac output and lower systemic vascular resistance. These findings can be
explained by the gender-specific differences in LV remodeling in obesity, as
reported by Rider et al. [146]. According to their study, obese men showed
predominantly concentric hypertrophy, whereas obese women exhibited both
eccentric and concentric hypertrophy. Association of visceral obesity and LV
concentric remodeling has also been reported in several later large population MRI
studies [147-149]. However, these studies did not report LV diastolic function.
The role of epicardial and pericardial fat in LV function
We found that MetS is strongly associated with an increased amount of VAT which
in turn is the best predictor of pericardial and epicardial fat. An increased amount
of epicardial fat is related to burden of atherosclerotic plaques, CAD and myocardial
ischemia [150, 151]. Epicardial fat as well as pericardial and myocardial fat all
correlated to LV concentric remodeling. Furthermore, our CMR study showed that
epicardial fat is associated with LV diastolic dysfunction. This is in line with earlier
findings based on echocardiography and computed tomography [92]. However,
when the effect of visceral or hepatic fat was considered, epicardial fat did not
remain as an independent predictor of LV diastolic dysfunction. Therefore, the
association of epicardial fat with impaired LV diastolic function is probably indirect
due to its close correlation with both hepatic and visceral fat depots.
Most studies have focused on epicardial adipose tissue, and a lesser role has
been left to pericardial or intrathoracic fat. In our study, pericardial fat correlated
with diastolic dysfunction even on a larger scale of parameters than epicardial fat.
It was the best marker of one of the three examined LV diastolic parameters, ratio
of early diastole, even when the effect of visceral and hepatic fat was considered.
Similarly, as a marker of ectopic fat accumulation, pericardial fat has been reported
to associate with insulin resistance and 10-year CAD risk more strongly than
epicardial fat [152]. Pericardial fat depot may reach considerable dimensions with
obesity, thus representing a mechanical challenge for the beating heart and
affecting cardiac dimensions and workload. While epicardial fat has shown to be an
active endocrine organ, the role of pericardial fat as a source of proinflammatory or
adipokine bioactive molecules is uncertain [95].
Role of liver fat on LV function
Our data revealed that LV diastolic dysfunction was associated with high liver fat
content, while systolic function remained unaltered. In contrast, Perseghin et al.
reported that LV morphological features were similar between high and low liver
TG content [127]. After our study and using comparable methodology, however,
results of a large (n=714) population-based study associated hepatic TG content
with LV diastolic dysfunction giving further support to our findings [153]. Recently,
association of NAFLD or NASH and LV diastolic dysfunction has also been reported
in several echocardiographic studies [154-157].  Notably, the changes may be
reversible as shown in a recent CMR and 1H-MRS study, where 12 weeks high-
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intensity interval training program led to decrease in hepatic TG content and
improvement of LV diastolic function [158].
Furthermore, our study showed that ectopic fat in all three cardiac sites
accumulated with increasing amount of both hepatic TG and VAT. Our study
suggests that visceral adiposity and hepatic fat lie at the root of the systemic
harmful effects and LV diastolic dysfunction. The data provide further evidence for
the model of two classes of ectopic fat depots with either systemic or local
deleterious effects on cardiovascular health [5]. Thus, both NAFLD and VAT seem
to influence CVD risk by associating with both metabolic risk and LV diastolic
dysfunction.
The pathophysiological mechanisms linking NAFLD with cardiac
complications contain a variety of derangements from subtle subcellular changes
to systemic changes including hemodynamic, metabolic, hemostatic, hormonal, and
cytokine abnormalities, as well as dysregulation in multiple organ systems [120].
These processes are not completely understood and reach beyond the scope of this
thesis.
LA dysfunction in MetS
We discovered that in MetS, LA function is decreased as measured by LA EF,
without the enlargement of LA. The decrease in LA EF indicates the presence of LA
mechanical remodeling, an entity with increasing interest in the recent literature
[74, 159]. When LA measurements were compared to patient outcomes, LA EF was
superior and incremental to LA volume regarding the assessment of mortality risk
in general population [160]. Lower LA EF has also been associated with a poorer
prognosis in patients with HF [161] and non-ischemic cardiomyopathies [162]. LA
remodeling can be reversible, especially at early stages, and may be treated with
medications such as angiotensin-converting enzyme inhibitors or angiotensin II
receptor antagonists [163].
In our study, except for blood pressure, all other components (waist
circumference, insulin resistance and dyslipidemia (low HDL)) of MetS were
related to LA dysfunction. Waist and VAT were better predictors of LA dysfunction
than BMI, thus emphasizing the role of visceral obesity in LA remodeling. In a recent
population-based study, LA enlargement was associated with visceral obesity, but
LA function was not evaluated [164].  In our study, liver fat was also associated with
lower LA EF, but the correlation did not remain significant after adjusting for age.
Insulin resistance is a key component of MetS associated with several
pathogenetic abnormalities that lead to HF and increased cardiovascular mortality
[45]. In our non-diabetic study population, insulin resistance was associated with
LA dysfunction as shown by inverse correlation of blood glucose and insulin levels,
and HOMA-IR index with LA EF. This is consistent with an earlier MRI study
reporting an association of T2DM and lowered LA EF [165].
Obesity and MetS are well-known risk factors of AF and decreased LA EF has
been shown to increase the risk for AF independent of LA size [161, 166].
Functional LA remodeling is one of the causes suggested as a factor preceding AF.
Evaluating LA function with a relatively simple 3ch CMR method that we
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introduced may hence provide valuable clinical information to find particularly
those obese persons at risk for developing AF or other cardiovascular events.
Myocardial TG content and cardiac energetics
Interestingly, myocardial TG content was not independently associated with LV
diastolic dysfunction when other cardiac fat deposits or hepatic TG or VAT were
considered. In line with our results, two studies in insulin-resistant women, both
without an assessment of epi/pericardial fat, reported the link between the
myocardial TG content and diastolic dysfunction as of borderline significance [141]
or negative [167]. Our findings challenge the concept of myocardial lipid
accumulation as an unambiguous marker of diastolic dysfunction, as suggested by
earlier studies in T2DM patients where myocardial TG content was associated with
impaired LV diastolic function [87, 88]. Likewise, McGavock et al. failed to
demonstrate any relationship between the degree of myocardial TG accumulation
and diastolic function in patients with T2DM [168]. In contrast to our findings,
Banerjee et al. reported recently a positive correlation between LV diastolic
dysfunction and myocardial TG content in mixed-gender cohort [169]. However,
they did not measure epi- or pericardial fat or hepatic TG content, or report
whether the finding was independent of VAT.
In our subjects with MetS, myocardial TG content was, however, increased up
to two-fold compared with the subjects without MetS. Notably, the range of
myocardial TG content (0.14-2.33%) was relatively narrow. Rather than a stable fat
deposit, myocardial TG is a highly dynamic lipid pool, where up to three or four-
fold increase has been reported following 48–72 h fasting in lean subjects [83, 170].
On the other hand, short-term lipid excess did not increase TG content in
cardiomyocytes [82]. In diabetic subjects, 16 weeks calorie restriction decreased
myocardial TG levels and improved diastolic function [170]. Hence, myocardial TG
content may be adaptive to both short and long-term dietary interventions, and it
may thus serve as a relatively rapidly changing reservoir of energy, in an analogous
fashion to intramyocytic TG of skeletal muscle [171].
Considering this, the effects of weight loss on myocardial TG content has
reported to be surprisingly weak. Gaborit et al. reported that during 6 months
follow up, bariatric surgery in morbidly obese patients had no effect on myocardial
TG content, although LV diastolic function was improved [172]. Similarly, diet
intervention and moderate weight loss over 24 months improved LV remodeling
but did not alter myocardial TG levels in overweight or obese postmenopausal
women [173].
In our study population, myocardial steatosis was not a key factor of LA
dysfunction, although an association of myocardial TG content with reduced LA EF
in 2D model was noted. To our knowledge, no earlier 1H-MRS studies exist where
myocardial TG content has been examined in atrial dysfunction or AF. For the atria,
energy substrate preference has not been investigated but it may not differ from
that in the ventricles [174].
The study design does not allow us to evaluate the molecular mechanisms
underlying cardiac steatosis. While 1H-MRS is a powerful method for detecting
abnormalities in lipid storage, it cannot differentiate between disturbances in lipid
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uptake on one hand and lipid utilization on the other. Therefore, the accumulation
of intramyocardial TG may result from the imbalance of FFA uptake and oxidation
in the heart. Heart and liver share the unique position of first-pass organ being
exposed directly to FFA flux from the visceral fat depots. Other potential sources
for FFAs are lipolysis of circulating lipoproteins by lipoprotein lipase, hydrolysis of
intramyocardial TG by adipose TG lipase, and uptake of lipids via VLDL receptors
[175-177]. Labbé et al. used dynamic positron emission tomographic imaging of
both heart and liver to follow-up the fate of dietary fatty acids in humans [178].
They demonstrated that obese subjects with impaired glucose tolerance displayed
both increased fatty acid uptake and oxidation of postprandial dietary fatty acids.
Thus, the oversupply of fatty acids from dietary fat can also be a significant source
for intramyocardial fat.
Normal heart utilizes FFAs and glucose as main energy sources with a ratio of
3:1 [179]. However, the heart is constantly switching between glucose and fatty
acid metabolism in response to prevailing metabolic and exercise conditions [95].
Therefore, maintaining metabolic flexibility is essential for the preservation of a
normal cardiac function. In the setting of obesity, the energy balance is shifted even
more from glycolysis toward the increased β-oxidation of fatty acids [180]. Under
aerobic conditions, fatty acid oxidation yields more adenosine triphosphate (ATP)
per gram of substrate but takes 10-15% more O2 per amount of ATP than glucose
[174]. Therefore, during chronic hypoxia and HF, ventricular metabolism shifts
from fatty acid to glucose utilization. Accordingly, we reported that in dilated
cardiomyopathy, myocardial TG is markedly lower than in control subjects with
comparable abdominal fat distribution [181]. Recently, Rayner et al. reported a
progressive decrease in PCr/ATP ratio across the increasing VAT quartiles
indicating disturbed myocardial energetics [143]. In addition, peak diastolic strain
rate behaved similarly, indicating LV diastolic dysfunction. The diastolic phase of
the cardiac cycle is more sensitive to energetic depletion than systolic phase due to
the higher energy demands of active calcium uptake. Therefore, it is logical that
compromises in myocardial energetics in MetS are linked to LV diastolic
dysfunction [143].
In MetS, the increased intramyocardial TG may reflect not only the passive
storage but also the enhanced demand of lipids due to the preference of using fat
more over glucose as the primary fuel of the heart. Theoretically, myocardial TG
content may, however, act ambiguously in obesity-related cardiac dysfunction, as
it may increase due to accelerated FFA uptake and β-oxidation, and decrease in
response to the higher energy demand, oxidative stress, and increased glycolysis.
In conclusion, understanding of the regulatory processes behind these changes
in cardiac substrate selection and utilization remain unclarified and the dynamical
role of intramyocytic lipids will merit further studies. As a future research interest,
31P-MRS could be combined with 1H-MRS to further examine the derangements in
cardiac energy balance in obesity and MetS.
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Study limitations
Our study population (n= up to 77) was relatively large for the meticulous pattern
of modern imaging studies. Yet, in terms of assessment of independent predictors
of LA and LV dysfunction, the sample size was quite small due to high
interrelationship of ectopic fat depots and components of MetS. To exclude the
effects of hormonal variability, our study population was limited to men which was
a clear limitation of the study. However, gonadal steroids play a major role in the
regulation of adipose tissue distribution and consequently have an impact on
gender-specific differences in LV remodeling in obesity [31, 146]. Subjects with
MetS were older than controls producing a potential source of bias for the
evaluation of cardiac steatosis and cardiac dysfunction. Still, our results remained
significant after adjusting for age. There was a clear difference in biomarkers
between subjects with and without MetS, however, the differences other than MetS
criteria might be significant confounders in terms of differences in LV structure and
function.
A limitation of 1H-MRS methodology was the narrow range of myocardial TG
content in healthy subjects which has been reported to be less than or about 1%
[182, 183]. Accordingly, myocardial TG content was low in most lean subjects and
this may underestimate its association with metabolic parameters as compared to
pericardial fat. Whether the measurement of myocardial TG content from the
ventricular septal wall corresponds to TG content of the LA myocardium is unclear,
limiting the investigations of cardiac steatosis in LA dysfunction.
Although the measurements of diastolic function consisted of multiple
parameters, they were based on LV short-axis cine images. Other methods, such as
trans-mitral velocity-encoded flow analysis, might have served as an internal
reference. However, pseudonormal E/A-pattern related to diastolic dysfunction
might be a pitfall of this technique. In our experience, velocity measurements are
easily subject to averaging errors because of data gathering time of several minutes
and intracycle variation.
Another source of bias is that the measurement of LA volume did not cover the
whole volume of LA but was based on a single image plane of 3ch images with the
third dimension taken into account by measuring the LA diameter in perpendicular
SA plane. Absolute LA volumes correlated well with those measured from SA
images with Simpson's method considered as gold standard in our small study
population, and the absolute LA volume values we obtained were comparable to
earlier CMR and multidetector computed tomography studies calculated with
Simpson's method [184-186]. Phasic LA function analysis could have been
informative to further evaluate the mechanism of atrial dysfunction and
remodeling.
Finally, the cross-sectional nature of the study design limits inferences of
causality.
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CONCLUSIONS
1. In MetS, myocardial TG content is increased but is also influenced by other
factors than the excess visceral obesity, e.g. by altered energy metabolism.
The best independent predictor of cardiometabolic risk factors is VAT.
2. MetS is associated with LV diastolic dysfunction and concentric LV
remodeling. Myocardial TG content is, however, not an independent
predictor of LV diastolic dysfunction.
3. Epicardial and pericardial adipose tissue as well as myocardial TG content
accumulate with increasing amount of both hepatic TG content and VAT.
Hepatic steatosis and VAT are associated with LV diastolic dysfunction.
4. MetS is associated with subclinical LA dysfunction without enlargement of
the LA. Moreover, LA dysfunction was associated with several contributory
factors of MetS including waist circumference, insulin resistance,
dyslipidemia, and VAT. The best independent predictor of LA dysfunction
is VAT. Notably, the role of myocardial TG remains inconclusive.
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